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Since the discovery of adult human mesenchymal stem cells in the late 1900’s, the 
potential of utilizing these cells in the clinic for cell-therapy applications has been an ever-
present goal. Unfortunately, clinical trials using these cells have garnered lackluster results 
with a high degree of variability in patient outcome and in many cases no difference 
between patients who received these adult stem cell or placebo. Various factors account 
for such results including the inability to properly control cell presence via the routine 
method of intravenous administration, the inability to control cell phenotype once the cells 
are injected into the patient and the harsh microenvironment cells are injected into. 
Biomaterials can provide solutions for these factors through engineering scaffolds to 
present needed signals to both encapsulated stem cells and the surrounding 
microenvironment. The objective of this project is to engineer bioartificial hydrogels 
presenting specific signals in the form of integrin-specific ligands and covalently-bound 
proteins to enhance vascularization and mesenchymal stem cell activity and efficacy in 
wound and disease models.  
We investigated the application of these bioarticifial hydrogels towards two 
different goals: 1) to enhance vascularization and bone regeneration in a critical size bone 
defect and 2) to enhance immunomodulation of encapsulated stem cells. For the first aim, 
cell-mediated degradable poly(ethylene) glycol-based (PEG) hydrogels were 





along with one of two types of adhesive peptides, either the α2β1 integrin-targeting 
‘GFOGER’ peptide or the mainly αvβ3 integrin-targeting ‘RGD’ peptide. These hydrogels 
were implanted within a murine segmental bone defect and bone repair monitored via 
microcomputed tomography and vascularization assessed via vessel perfusion. We 
hypothesized that incorporation of VEGF and different peptides would result in a 
differential effect on vascularization which would enhance both stem cell therapy and bone 
repair. For our second goal, we synthesized PEG-based hydrogels functionalized with a 
tethered form of the protein interferon-gamma (IFN-γ), a protein known to enhance the 
immunomodulatory properties of hMSCs. The capacity for these hMSC-laden hydrogels 
to modulate immune responses was tested in vitro with monocytes and T-cells before 
assessing the platform in a colonic wound model. We hypothesized that covalent tethering 
of this protein onto hydrogels would result in enhanced immunomodulation by 
encapsulated stem cells which would translate into more rapid wound resolution.  
For our first goal, we found that hydrogels presenting the α2β1 ligand ‘GFOGER’ 
resulted in enhanced vascularization of bone defects compared to hydrogels presenting the 
αvβ3 ligand ‘RGD’ in the absence of vasculogenic protein. For our second goal, we found 
that hydrogels functionalized tethered IFN-γ enhanced the immunomodulatory properties 
of encapsulated hMSCs which led to enhanced tissue resolution in a colonic wound model. 
Together, our findings elucidate novel ways to enhance adult stem cell efficacy and further 





CHAPTER 1. SPECIFIC AIMS 
1.1 Introduction: 
Human mesenchymal stem cells (hMSCs) are a widely studied cell type that are now 
in over 493 ongoing or completed clinical trials according to the database of the National 
Institutes of Health [1]. HMSCs are attractive for regenerative medicine applications due 
not only to their ability to differentiate down several lineages but also their 
immunomodulatory activities and their beneficial paracrine effects [2-4]. Indeed, while 
various studies have investigated how MSCs contribute directly to regeneration of tissue 
through differentiation [5-7],  more recent studies have focused instead on the ability of 
hMSCs to curtail and control the microenvironment through paracrine signaling and 
immunomodulation as can be seen in their utilization in multiple autoimmune diseases [8]. 
Regardless of the mechanism(s) of action, successful application of hMSCs in the clinic 
faces hurdles including issues related to sourcing and procurement, as well as challenges 
on issues related to the actual efficacy of the cell-therapy [9, 10].  
In terms of efficacy, hMSC therapy is fraught with problems relating to poor survival, 
retention and engraftment of hMSCs in vivo, and donor-to-donor variability [10]. 
Twoissues that lead to poor outcomes on these various metrics is the large number of cells 
that die upon implantation and the inability to control the cells once implanted in vivo. In 





delivered, there is little that clinicians can do to control the fate of the transplanted cells. In 
many cases, infusion or implantation of MSCs results in the majority of MSCs dying 
shortly after implantation due, at least in part, to a lack of vascularization. Additionally, 
having the ability to control the hMSCs or their microenvironment once implanted would 
allow researchers the ability to manipulate the cells in order to increase their efficacy 
toward various clinical outcomes. To this end, biomaterials can be used as a cell delivery 
and encapsulation vehicle precisely to engineer the microenvironment in which both the 
stem cell resides as well as to control its interaction with the recipient system. Whereas 
biomaterials have been used in recent years for this purpose, there remains a lack of 
understanding of what specific cues and signals the host tissue and encapsulated hMSCs 
need embedded within the biomaterial in order to enhance the efficacy of different cell 
therapies. The two main objectives of this project are thus to 1) understand the interplay of 
integrin-binding peptides and the vasculogenic factor VEGF within a biomaterial to 
increase vascularization and bone regenerationwithin a critical-size bone defect and 2) 
engineer a biomaterial with an tethered inflammatory protein to enhance the 
immunomodulatory properties of encapsulated hMSCs. Our hypothesis for the two 
objectives are respectively 1) functionalization of polyethylene glycol (PEG) hydrogels 
with different integrin-specific peptides and VEGF will modulate vascularization and 
associated bone regeneration and 2) functionalization of PEG hydrogels with a 





of hMSCs and thus enhance their efficacy for treating colonic wounds. These objectives 
will be accomplished through the following two aims: 
1.2 Specific Aim 1: Engineer hydrogels functionalized with integrin-specific 
peptides and vascular endothelial growth factor (VEGF) to investigate the 
interplay between these two factors on vascularization and bone regeneration 
of a murine segmental defect.  
We will utilize two different synthetic peptides exhibiting varying integrin-binding 
specificity: the fibronectin-derived RGD peptide for mainly αvβ3 binding or the collagen-
mimetic GFOGER peptide for α2β1 binding. These peptides will be incorporated into 
hydrogels by covalently tethering them to a 4-arm poly (ethylene) glycol-maleimide (PEG-
MAL) macromer through Michael-type addition. VEGF will also be tethered onto the 
macromer through similar Michael-type addition of its free cysteine. Macromers will then 
be cross-linked together with bi-cysteine presenting protease-degradable synthetic 
peptides. With this platform in place, we will initially test the bioactivity of the tethered 
VEGF through in vitro studies on its proliferative and network-forming effect on human 
umbilical vein endothelial cells (HUVECs). After we have proven the retention of the 
tethered VEGF’s bioactivity, we will implant these hydrogels within a murine critical-size 
radial segmental bone defect and monitor longitudinal bone regeneration through 
microcomputed tomography (µCT). Vascularization will also be analyzed via µCT analysis 





hydrogels functionalized with VEGF will have differential effects on vascularization of the 
defect and thus lead to differential bone regeneration.  
1.3 Specific Aim 2: Engineer covalently bound IFN-γ hydrogels to increase 
immunomodulatory properties of encapsulated hMSCs for the treatment of 
colonic wounds. 
We will utilize the PEG hydrogel platform described in Aim 1 to test the ability for 
covalently tethered interferon gamma (IFN-γ) to modulate the immunomodulatory 
properties of encapsulated MSCs. We will encapsulate hMSCs into the hydrogel and 
analyze how tethered IFN-γ influences hMSC polarization into an immunomodulatory 
state by both flow cytometric analysis of specific markers as well as paracrine cytokine 
secretion. We will then analyze the ability for bound IFN-γ to modulate hMSC-based 
CD4+ T-cell proliferation and monocyte and macrophage polarization. We hypothesize 
that bound IFN-γ will differentially regulate encapsulated hMSC immunomodulatory 
properties. Based on these preliminary results, we will select the hydrogel formulation most 
suitable for increasing the immunomodulatory properties of encapsulated hMSCs and 
investigate how the selected conditions influence the efficacy of the biomaterial construct 
for treating colonic wounds in immunodeficient mice. We will induce colonic wounds in 
mice through a custom-engineered colonoscope device that allows for precise tearing of 
the epithelial layer. Colonic wounds will be induced through this method followed by 





treatment will be assessed through the following parameters: 1) wound closure over the 
course of 14 days through colonoscope assessment; 2) cytokine analysis of surrounding 
tissue for pro- and anti-inflammatory markers; 3) histological assessment of the wound 
area at 14 days for signs of wound resolution.  
1.4 Significance 
This work is significant as it elucidates novel ways to engineer biomaterials to enhance 
the efficacy of adult stem cells in disease models. Current use of stem cells in the clinical 
is largely restricted to systemic infusion in which localization as well as control of 
microenvironmental cues is absent. Through the research presented here, we show how 
engineering the microenvironment surrounding mesenchymal stem cells through 
biomaterials engineering approaches, we can significantly alter and shape stem cell 





CHAPTER 2. LITERATURE REVIEW* 
*Partly adapted from Garcia, JR. and A.J. Garcia, Biomaterial-mediated strategies 
targeting vascularization for bone repair. Drug Deliv Transl Res, 2016 6(2): 77-95 [11] 
2.1 Characterization of human mesenchymal stem cells (hMSCs) 
By definition, stem cells are cells that exhibit two distinct properties: 1) the ability 
for self-renewal and 2) the ability to differentiate into other cell phenotypes or the 
characteristic known as multipotent (or pluripotent). Human mesenchymal stem cells were 
first discovered in the middle to late half of the 20th century by Friedenstein and colleagues 
through observation of a subset of isolated bone marrow cells that rapidly adhered to tissue 
culture plastic and exhibited a fibroblast-like appearance [12-14]. Since this initial 
discovery, many more parameters have been identified aimed at providing a general 
guideline for researchers to conclusively label a cell as a mesenchymal stem cell. 
According to the International Society for Cellular Therapy (ISCT), human mesenchymal 
stem cells must meet three main criteria: 1) Adherence to plastic 2) a specific antigen 
profile and 3) differentiation potential to three main lineages, namely, osteogenic, 
adipogenic and chondrogenic lineages [15]. In regards to the specific antigen profile, MSCs 
must be positive for cluster of differentiation (CD) markers CD105, CD73 and CD90 while 





As described before, hMSCs were first isolated from bone marrow and thus initial 
studies centered on bone marrow as the primary source of hMSCs [3, 16, 17]. Due to 
various issues including the difficulty in procuring bone marrow, other sources of human 
adult or neonatal tissue such as umbilical cord blood, dental pulp, Wharton’s jelly and 
placenta among other sites have been analyzed for the presence of mesenchymal stem cells 
[18-22]. Notably however, the most common source of MSCs aside from bone marrow has 
become adipose tissue due to both the presence of MSCs as well as the relative ease in 
procuring the tissue as adipose tissue is normally discarded in many elective surgeries [23]. 
While MSCs from each of these sources exhibit the criteria for definition of a mesenchymal 
stem cell described previously, recent studies have noted that the cells from these sources 
can have differences in phenotype. Kern et al discovered that MSCs isolated from 
umbilical cord blood exhibited significantly higher potential for proliferation and 
population doubling compared to MSCs isolated from bone marrow and adipose tissue but 
failed to differentiate into adipose tissue [24].  In addition to tests for proliferation and 
differentiation, other studies have focused on functional effects on other cell types. Puissant 
and colleagues compared the ability for either bone marrow-derived or adipose-derived 
MSCs to inhibit the proliferation of lymphocytes in co-culture and found that both cell 
types halted proliferation at similar levels [25]. Yoo and colleagues affirmed this finding 
and added that umbilical cord blood-derived and Wharton’s jelly-derived MSCs also 
inhibit lymphocyte proliferation to similar levels as bone marrow-derived and adipose-





sources of MSCs for both their ease of procurement as well as their functionality, as MSCs 
increasingly make their way into clinical use, more studies will have to be done regarding 
their efficacy in the various disease models.  
2.2 Bone repair and use of hMSCs 
2.2.1 Epidemiology and mechanisms of bone repair 
In the United States alone, there is an estimated 7.9 million fractures that occur 
annually costing over $21 billion [27]. Of the 7.9 million annual fractures, approximately 
5-10% exhibit either delayed or impaired healing and a further 15% of these continue on 
to the point of non-union where the broken bone does not fully heal [28]. For patients in 
which their fracture exhibits impaired healing, this can translate into higher medical costs 
as well as a lower standard of living. Because of this, there is a demand for research into 
methods and treatments that can increase the success rate for bone healing. 
The process of bone healing is highly orchestrated one that falls into two categories: 
endochondral and intramembranous ossification. Endochondral ossification, the process 
through which all long and load-bearing bones in the body are generated and is 
characterized through development by a cartilage intermediary, initiates through migration 
and differentiation of mesenchymal stem cells (MSCs) into chondrocytes in part through 
activation and suppression of the transcription factors Sox9 and β-catenin, respectively 





transcription factor, and ultimately undergo hypertrophy through activation of Runx2 
followed by apoptosis following secretion of collagen and proteoglycans. Prior to 
apoptosis, these hypertrophic chondrocyte cells secrete a synchronized cascade of 
chemokines and cytokines that recruit endothelial cells and associated vasculature. The 
invading vasculature then allows for recruitment of osteoclasts, which subsequently 
remove the cartilaginous matrix and allow for osteoprogenitors to migrate to and deposit 
calcium and bone matrix into the remnants of the matrix [30]. While osteoprogenitors 
originate from the same cell type as the initial chondrocytes that laid down the cartilaginous 
matrix, early activation of the transcription factor Runx2 in the absence of Sox9 followed 
by upregulation of osterix, alkaline phosphatase and osteopontin cause MSC differentiation 
down the osteogenic lineage [31]. 
Throughout this process, the spatiotemporal regulation of growth factor activity 
provides necessary cues for proper skeletogenesis. Notably, vascular endothelial growth 
factor A (VEGF) along with the family of bone morphogenetic proteins (BMPs) and 
fibroblast growth factors (FGFs) are central to this process. Initially, BMP 2, 4, 7 and 9 all 
aid in the initiation of chondrocyte differentiation and cartilage development; deletion of 
these growth factors leads to gross absence of most skeletal components [32, 33]. Once 
chondrocytes begin to undergo hypertrophy, their VEGF mRNA expression increases with 
subsequent secretion of the protein resulting in elevations in the proliferative capacity of 
nearby chondrocytes as well as inducing vascular invasion into the ischemic cartilaginous 





angiogenesis, ossification and results in massive cell death in chondrocytes, whereas 
reverting this blocking treatment restores normal bone formation [34-36]. Coinciding with 
this increase of locally secreted VEGF, expression of FGF18 is increased and acts as a 
negative regulator of chondrocytic proliferation through FGF receptor 3 (FGFR3) [37]. 
Mice lacking either the Fgf18 or Fgfr3 gene exhibit heightened levels of chondrocyte 
proliferation and associated lower levels of osteogenic differentiation from invading MSCs 
into the ossification front. The fact that VEGF increases the proliferation of chondrocytes 
while the presence of FGF18 counteracts this process indicates a tightly regulated process 
in which it has been postulated that VEGF expression is controlled through activation of 
FGFR3 [38].  
In contrast to endochondral ossification, intramembranous ossification forms bone 
without a cartilage intermediary and is the mechanism by which all flat bones, including 
the cranial and clavicle bones, are formed [39]. In this process, MSCs directly differentiate 
into osteoblasts and secrete bone matrix into the surrounding ECM. Prior to their 
differentiation, MSCs destined to become osteoblasts begin to condense at the area of 
ossification with various FGFs being highly expressed in center of ossification [40]. 
Following condensation, spatiotemporal concentrations of BMP2, BMP4, and BMP7 
activate the expression of Runx2 which acts as a transcription for further osteogenic 
differentiation [41]. Expression of late-markers for differentiation including osteocalcin 
and osteopontin requires the initial activation of Runx2. In regards to vascularization, the 





surrounding blood vessels to invade the mesenchymal condensation near the time of initial 
ossification [42]. As ossification occurs surrounding the blood vessels, the mesenchymal 
stem cells not involved in ossification at the time migrate outward. Blood vessels continue 
to extend toward these migrating cells with mineralization occurring near these sprouting 
vessels [42].   
2.2.2 Use of mesenchymal stem cells for bone repair 
Due to their ability to differentiate down an osteogenic lineage, MSCs have long 
been recognized as a clinically relevant cell for bone regenerative applications. In 1998, 
Bruder et al. implanted bone-marrow isolated mesenchymal stem cells within a 
hydroxyapatite carrier into femoral defects in rats and found that implantation of these cells 
increased the strength of regenerated bone compared to vehicle only controls [43]. In that 
same year, Bruder and colleagues also demonstrated efficacy of autologous mesenchymal 
stem cells when applied within the larger canine animal model [44]. Since then, many more 
studies have been conducted in which mesenchymal stem cells within a carrier were 
utilized to treat bone defects [45-48]. While MSCs were known to undergo osteogenic 
differentiation in vitro, throughout these initial studies, it was unknown whether delivered 
MSCs underwent osteogenic differentiation once implanted within the defect site. In a 
recent study however, Vila et al. demonstrated, using a dual-luciferase tracking system in 
which MSCs were transduced to express luciferase driven by constitutive and osteocalcin 





upregulated their expression of osteocalcin, a late-marker for osteogenic differentiation 
[49]. 
Whereas multiple studies have demonstrated MSCs being efficacious in 
regenerating bone in multiple models, it is worthy to note that there are various studies 
showing the opposite effect. Niemeyer et al. conducted a study in which autologous MSCs 
were implanted within ceramic scaffolds in a rabbit calvarial defect. The researchers found 
no difference in the mechanical strength of regenerated bone between groups containing 
the autologous MSCs and acellular scaffolds [50]. Seebach and colleagues also 
demonstrated in a rat femoral defect model that beta-tricalcium phosphate scaffolds loaded 
with bone-marrow derived MSCs had no difference in bone volume and ultimate load 
compared to acellular beta-tricalcium phosphate scaffolds [51]. In another study, Zou et al 
showed that MSCs delivered within a gelatin sponge had no effect on either bone volume 
or bone mineral density compared to acellular gelatin implants in a rat calvarial defect [52]. 
Altogether, these studies and others [53] show that over a range of bone defect models, 
assessment metrics and delivery vehicles for the MSCs, there remains a large discrepancy 
over the efficacy of MSCs and the overarching question remains as to if MSCs 
meaningfully and significantly enhance bone repair.   
2.2.3 Factors affecting MSC efficacy in bone repair 
With the discrepancies in MSCs for bone repair in mind, it is important to 





break down the factors into categories for ease of analysis. In any of these experiments, 
there are 4 main categories to consider: 1) the quality of cells being used prior to 
implantation 2) the method and material for cell delivery 3) the model and surgical 
procedure and 4) what occurs in the implant following the surgery. While much can be 
discussed regarding the first three categories described, specifically the quality of cells 
used as there has been enormous amount of research recently going into looking at the vast 
differences bona fide MSCs have from batch to batch, we will focus on the fourth category 
described: understand what occurs to MSCs post-implantation and discuss how 
engineering the material used to deliver the cells can potentially lead to enhanced efficacy 
of cells once implanted. In this section, we will be focusing on two major issues regarding 
stem cell use once implanted: 1) the hostile environment present in damaged tissue in 
which MSCs are implanted and how that affects MSC viability and 2) the lack of control 
once MSCs are implanted. For the latter case, we will explore the different cues, both 
chemical and physical, that cells sense that affect their phenotype. We will end this section 
by discussing how biomaterials can be made to address these two issues.  
2.2.3.1 Oxygen and nutrient deprivation following injury 
Many types of tissue defects and injury but specifically bone defects exhibit a 
difficult environment for cells to grow. In many cases of injured bone in which non-union 
occurs and intensive therapy is necessitated, the local vascular network has been destroyed 





turn increase the chance of a delayed-union occurring [55]. MSCs delivered into ischemic 
environments have been noted to exhibit increased levels of cell death compared to MSCs 
in more normoxic environments [56]. Indeed, studies that have tracked the retention of 
MSCs in bone defects through bioluminescence and constitutively expressed luciferase 
show that within 1-2 weeks of MSC implantation, a vast majority of the cell signal is absent 
[48, 57, 58]. The lack of MSC survival in bone defects thus poses a potentially large factor 
in limiting the efficacy of MSCs for bone repair.  
2.2.3.2 Cues for directing stem cell phenotype: Chemical 
Another issue when delivering MSCs into bone defects is the inability to control 
cell fate and phenotype once delivered. In vitro, stem cells are routinely manipulated using 
growth factors or cytokines added to the media. The semi-known environment inherent in 
the in vitro experiment allows for a high degree of user-defined control of stem cell 
phenotype. In vivo however, the lack of control over the microenvironment as well as the 
complicated interplay between endogenous and exogenously delivered cells results in an 
extreme lack of control over the delivered stem cell phenotype. To this end however, 
multiple studies have investigated the different cues that control stem cell fate with the 
potential utilization of these cues to direct cell phenotype in vivo. External cues can be 
grouped into two broad categories: 1) chemical and 2) physical cues. Chemical cues can 
be defined as any cue in the form of a soluble factor such as a small molecule drug or 





mechanical stimulus on the cell, usually through the form of mechanotransduction 
molecules such as integrins. While chemical cues can be added to media for in vitro 
purposes, utilizing chemical cues to direct cell fate in vivo requires different strategies.  
One strategy used has been to load known amounts of growth factor or cytokines 
into a stem cell-laden scaffold and investigate how the release kinetics and dose of the 
growth factor affect encapsulated cell phenotype. This technique has been successfully 
used in a variety of studies looking at the differentiation of MSCs down chondrogenic and 
osteogenic lineages through encapsulation of both MSCs and various proteins including 
transforming growth factor-beta (TGF-β), dexamethasone and bone morphogenic protein 
(BMP) [59-63]. A different take on this strategy is to somehow tether, through covalent 
interactions or otherwise, a prescribed molecule or biologic of interest directly onto the 
scaffold. Rather than having the drug or protein of interest release through strictly 
diffusion, this deviation allows for a higher degree of control based on the engineering of 
the tethering itself. Nuttelman et al. has demonstrated that covalently tethering 
dexamethasone, a powerful factor in osteogenic differentiation of MSCs, onto the PEG 
backbone of a PEG-based hydrogel increases the osteogenic differentiation of encapsulated 
MSCs [64].  In lieu of covalently tethering a molecule onto a scaffold, controlling the 
presence and kinetics of a growth factor through binding domains is also a viable option. 
Martino and colleagues engineered a fragment of fibronectin that held both an integrin-
binding domain and a growth factor-binding domain [65]. Through this approach, the 





MSCs into this scaffold along with either platelet derived growth factor (PDGF)-BB or 
BMP-2 [65]. 
2.2.3.3 Physical cues for directing stem cell phenotype: Stiffness 
In addition to chemical cues, physical cues have also been explored as a potential 
lever in inducing and altering MSC phenotype in vivo. It is important to make the 
distinction that while physical cues fundamentally translate into mechanical stimulus on a 
cell, the breadth of research in this topic span three broad categories: 1) stiffness of a 
material 2) topography and 3) ligand-specific interactions on a cell. The relationship of 
stiffness to the differentiation potential of a mesenchymal stem cell was first observed in 
2006 in a seminal paper by Adam Engler and Dennis Discher [66]. In the study, Engler and 
colleagues seeded MSCs on substrates spanning stiffness values from 0.1 to 40 kPa and 
found that the cells on different stiffness substrates exhibited significantly different 
expressions of lineage-specific proteins [66]. On soft substrates, MSCs tended to express 
proteins consistent with a neurogenic phenotype while on stiff substrates, MSCs exhibited 
proteins consistent with an osteogenic phenotype. Since this finding, future studies have 
also shown other adult stem cells to act in a similar manner [67]. For example, muscle stem 
cells exhibit differences in proliferation and differentiation when seeded on substrates of 
different stiffness [68]. For many years, the molecular mechanism behind the ability of a 
cell to ‘feel’ its underlying matrix was not completely understood. A recent study however 





soft substrates, the underlying ECM deforms easily which causes the force-loading rate on 
the integrin bond to be low. This thus causes the unbinding of the integrin-ECM bond to 
be based on the intrinsic unbinding rate rather than an excessive force load ripping the 
bond. On high stiffness substrates in contrast, the high force-load rate causes an increase 
in integrin-ECM bond breakage that creates a reinforcement phenomena where additional 
integrins are recruited to the site through force-induced conformational changes in 
cytoskeletal proteins or mechanostabilization of integrin-clusters [70-72]. 
2.2.3.4 Physical cues affecting stem cell phenotype: topography 
In addition to stiffness, topography has also been shown to have a significant effect 
on MSC phenotype and differentiation. The general idea behind topography influencing 
cell phenotype revolves around the finding that cell shape is a significant factor in cell 
function. One of the first observations of this phenomena was in 1978 when Folkman and 
Moscona regulated cell shape through changing the adhesivity of tissue culture plastic [73]. 
The different cell shape resulting from the differences in adhesivity were then correlated 
with DNA synthesis [73]. Future work has built on this premise through a variety of 
techniques including micropatterning cell adhesive areas onto a surface and engineering 
surfaces with different topographical cues such as grooves or roughness [74-77]. Similar 
to the other mammalian cell types used in the preliminary studies of cell shape, MSCs also 
show a dependence of cell shape on their function and phenotype. Through micropatterning 





showed a significantly greater degree of adipogenic differentiation than osteogenic 
differentiation while MSCs on an adhesive island size of 10,000 µm2 showed a greater 
degree of osteogenic differentiation than adipogenic differentiation [78]. This observation 
was further attributed to the increased activity of RhoA and RhoA kinase (ROCK) in spread 
cells on the larger islands than unspread cells on the smaller islands [78]. Rather than 
patterning adhesive moieties on planar surfaces, surface engineering of topographical cues 
such as grooves, troughs and roughness also exhibits a significant effect on MSC 
phenotype. Dalby et al. demonstrated that MSCs cultured on randomized  poly(methyl 
methacrylate) (PMMA) nanopatterns showed significantly increased amount of osteogenic 
markers compared to ordered nanopatterns of the same material [79].  
2.2.3.5 Physical cues for directing stem cell phenotype: Integrin-ECM interactions 
The previous two physical cues discussed, that of stiffness and topography, are in 
theory, non-discriminatory in relationship to the specific cell-matrix interaction molecules. 
That is, the stiffness or topography alterations one makes may not favor a certain type of 
integrin-ECM interaction. The last type of physical cue discussed will be that of 
specifically engineering a material to activate a predetermined set or class of integrin 
molecules. We will discuss here the following two topics related to integrins: 1) what are 
integrins and how are they classified and 2) how do integrins function.  
 Integrins consist of one of the key classes of molecules that mechanically link the 





consisting of a α- and β- subunit brought together through non-covalent interactions [80]. 
While there are 8 β subunits and 18 α subunits, together, they can form 24 distinct integrins 
(Fig. 1) [81]. These 24 distinct integrins can be further categorized by either the types of 
cells that express the integrins at appreciable levels or the main ligand molecule binding 
the integrin. In the former case, integrin expression on a specific subset of cells results in 
differential population adhesion based on the cell types in the population. This is the case 
for the β2 subunit which is mainly found on leukocytes and is an important regulator of 
extravasation of the cells from the blood stream to regions to regions of inflammation [82, 
83].  By solely isolating the β2 subunit to a class of cells, non-leukocytes are prevented 
from attaching to and interacting with ligands found on the endothelial surface. Another 
method of classifying integrins can be via the specific protein ligand(s) through which the 
integrins mainly bind to. There are a variety of ligands found in the ECM including 
collagen, fibronectin, fibrinogen and vitronectin as well as many others that have been 
extensively studied to discover which integrins bind to which ligands and with what affinity 
[84]. It is important to note that most integrins can bind to several ECM proteins. The 
combination of the number of distinct integrin pairs, the differing affinities each integrin 
has to a variety of ligands and the differential expressions on subsets of cells creates a 







Figure 1: Integrin family as classified by different subpopulations of cells expressing each 






As a class of adhesion molecules, integrins function in a similar fashion to one 
another in that they adhere to and exert forces on the extracellular matrix (ECM) that in 
turn get translated into biochemical signalling inside the cell [85]. The method in which 
this happens occurs through two dynamic and related processes termed “outside-in 
signalling” and “inside-out signalling” [86-88]. To understand outside-in signalling, it is 
important to understand the structure of integrins. Integrins consist of large extracellular 
domain and a smaller intracellular domain which, by itself, is devoid of catalytic activity 
[89]. Upon presentation of a ligand in the extracellular space, integrins bind to the ligand 
and begin forming a cluster [90]. The clustering of intracellular domains enables the 
generation of a focal adhesion which is a conglomerate of adaptor proteins including talin, 
paxillin, vinculin and focal adhesion kinase (FAK) [91, 92]. These adaptor proteins have 
binding sites for the cytoskeletal actin filaments as well as a myriad of phosphorylation 
that initiate downstream signalling [93, 94]. Thus, outside-in signalling involves the 
transmissions of signals from outside the cell (ECM ligands) into biochemical signals 
through the integrin. In contrast, inside-out signalling involves altering the extracellular 
domain conformation of integrins and thus their affinity to ECM ligands. For 
conformational changes to be induced on the extracellular portion of integrins, it must start 
at the intracellular domain which, as noted above, is devoid of catalytic activity. Thus, 
inside-out signalling necessarily must proceed through the adaptor proteins that bind to the 
intracellular domain. One of these important adaptor proteins that contribute to inside-out 





prevented from associating with integrins [95, 96]. Upon cleaving of the closed formation 
through a variety of potential pathways, talin is released from its closed conformation and 
integrin and cytoskeletal binding sites become accessible [95]. Binding of talin to the 
cytoplasmic tail of β integrin subunits has been subsequently shown to induce a 
conformational change in the extracellular portion of the integrin and increase its affinity 
[97]. Other proteins such as the proteins within the kindlin family have also been identified 
as important regulators of inside-out signalling and integrin activation through a similar 
process as talin [98, 99]. While the intricacies of inside-out signalling are still being 
elucidated, an important question is that of what signals or pathways activate the adaptor 
proteins that then activate integrins? Research into this has shown that there exists an 
incredibly interwoven state of crosstalk between integrins and growth factor receptors and 
receptor tyrosine kinases [100]. This crosstalk can occur through either downstream 
pathways activated by cytokines or through direct interaction of integrins with the 
membrane-bound growth factor receptors. In the former case, various growth factors and 
cytokines such as those found in serum and specifically epidermal growth factor (EGF), 
insulin-like growth factor-1, and tumor necrosis factor alpha (TNF-α) have been identified 
as altering the affinity state of integrins [101-104]. Importantly, VEGF has also been 
implicated in altering the affinity state of integrins and thus consists of a potential lever 
through which growth factors and integrin activation can work together to achieve a desired 
outcome [105, 106]. Crosstalk also occurs directly between growth factor receptors and 





the affinity of the growth factor receptor to its substrate. Receptors for platelet derived 
growth factor-β (PDGF-β) and VEGF for example localize with the β3 subunit upon which 
activation of the β3 subunit potentiates resultant VEGF-induced cellular functions [107-
109]. Given the clearly interwoven state of crosstalk between growth factors and 
specifically that of VEGF and integrins, it is clear that further elucidation and utilization 
of this crosstalk is merited.  
2.2.4 Role of biomaterials in enhancing MSC efficacy 
To reiterate the main takeaway from this section, MSC use in bone repair is 
hampered for two main reasons: 1) the hostile environment within damaged tissue in which 
MSCs are implanted and 2) the lack of appropriate control over cell phenotype once MSCs 
are delivered into a defect. Biomaterials have been explored as avenues to solve these two 
issues.  In this section, we will explain the state of the biomaterials field as it pertains to 
these two problem areas. 
2.2.4.1 Role of biomaterials in enhancing MSC efficacy: vascularization  
As stated earlier, tissue injury results in the destruction of a vascular network and 
thus the limited availability of necessary nutrients. To confront this issue, biomaterials have 
been engineered to address two main problems: 1) supplying necessary nutrients, notably 
oxygen, to delivered cells in the short-term and 2) supplying necessary signals to induce 





the former strategy, biomaterials have been engineered to generate oxygen to supply 
encapsulated cells through either the use of peroxides or perfluorocarbons [110-112]. 
Pedraza and colleagues engineered polydimethylsiloxane (PDMS) disks containing 
calcium peroxide which, when exposed to aqueous solutions, generate oxygen through the 
reaction between the peroxide and water [113]. The researchers tested this platform with 
pancreatic islets and showed that the oxygen-generating biomaterial significantly 
decreased hypoxia-induced islet death compared to the non-oxygen-generating biomaterial 
[113].  Specifically within a bone radial defect, Kimelman-Bleich et al. demonstrated that 
BMP-2-expressing MSCs resuspended in a hydrogel supplemented with oxygen-
generating perfluorotributylamine exhibited heightened early-term cell survival and 
enhanced bone mineral density compared to cells in a hydrogel lacking the oxygen-
generating compound [114]. Notably however, the researchers showed that at one week 
post-implantation, there ceased to be differences in cell number between the oxygen-
generating and non-oxygen-generating group and that while differences arose in bone 
mineral density, there were no differences in bone volume [114]. The lack of differences 
between cell numbers at longer time-points may signal the need for the biomaterial to 
supply signals to enhance vascularization at longer temporal time-points.  
This thus brings us to our second point: biomaterials that supply signals to enhance 
the speed at which vascular remodelling takes place within damaged tissue and specifically 
bone. One of the most widely used approaches for the induction of vascular invasion is 





BMP2, BMP7, PDGFB and TGFB1 have all been explored to increase the early onset of 
vascular invasion with the most prominently utilized growth factor being VEGF [115]. 
VEGF is a potent angiogenic/vasculogenic growth factor and exerts its effects through 
interacting with two receptor tyrosine kinases, VEGFR1 (otherwise known as Flt1) and 
VEGFR2 (otherwise known as Flk1) [116]. Activation of these receptors in endothelium 
causes destabilization of the junctions holding endothelial cells in order to facilitate 
angiogenesis. Once broken down, VEGF acts as a chemotactic factor as well as signals for 
the proliferation of endothelial cells. One of the first studies investigating VEGF for bone 
regeneration showed in a fracture model in mice that treatment with a soluble VEGF 
receptor blocking endogenous VEGF activity impaired new bone formation [117]. 
Additionally, when VEGF was continuously delivered to critically-sized bone defects in 
rabbits over the course of seven days via a subcutaneously implanted osmotic pump, 
significant bone regeneration was observed in comparison to no VEGF treatments. One of 
the drawbacks with this study, however, was the supraphysiological doses of VEGF 
required to induce bone regeneration as high microenvironmental concentrations of VEGF 
results in the formation of aberrant and leaky neovasculature [118, 119].  
To optimally control the kinetics and distribution of therapeutic protein release and 
subsequently lower the total delivered dose, biomaterials have been engineered to achieve 
tailored and sustained delivery profiles. A common strategy is absorbing and entrapping 
growth factors within biomaterial scaffolds synthesized with pore sizes that would dictate 





invasion of microvasculature and osseointegration in a murine calvarial defect [120]. 
Similarly, incorporation of VEGF into a PLGA scaffold followed by coating with bioactive 
glass showed increased infiltration of blood vessels with an increase in bone mineral 
density in a rat calvarial defect compared to scaffolds without VEGF [121].  
The effectiveness of therapeutic proteins depends heavily in the spatial and 
temporal microenvironmental concentrations of the protein(s). This delivery profile in turn 
is controlled by the total dose incorporated within a material, the kinetics of release, and 
the persistence and stability of the protein. In most therapies, including those in which 
therapeutic proteins are absorbed or incorporated into materials without any covalent or 
affinity-mediated tethering, release kinetics are defined by non-specific interactions 
between the protein and the material. Scaffold porosity, adsorption parameters, and affinity 
to the scaffold control the release of these proteins. In this sense, the kinetics of protein 
release can be thought of as a ‘materials-driven process’ with the advantage being that one 
can precisely engineer a material, by regulating pore size for example, to fit a distinct 
release profile. The issue, however, is that this process is independent on the particular 
protein-material pair and the surrounding biological environment. To engineer biomaterials 
to effectively deliver therapeutic proteins, it may be beneficial to consider how these 
growth factors are typically presented in tissue repair.  
Following vascular injury, platelets, neutrophils, and macrophages respond to the 





As matrix metalloproteinases (MMPs) work to degrade this provisional matrix, ECM-
bound growth factors are released and dictate the appropriate course of action for 
surrounding cells to heal the wound and revascularize the region [123]. It is this 
spatiotemporal control of MMP activity followed by the spatial regulation of growth factor 
concentration by ECM degradation and presentation that, among other factors, controls 
proper wound revascularization. Mimicking this ECM-embedding strategy can prove 
useful in aptly controlling angiogenic growth factor presentation within bone defects.  
A ground-breaking study by Hubbell and colleagues demonstrated the engineering 
of a completely synthetic scaffold in which BMP2 had been entrapped within an MMP-
sensitive hydrogel and used to regenerate bone within an orthotopic model [124]. In vitro, 
hydrogels exhibited BMP2 release kinetics which were highly dependent on gel 
degradation with 90% of the protein being retained in a saline solution whereas addition of 
the proteolytic MMP-2 induced 100% protein release. BMP2-loaded MMP-sensitive 
hydrogels also exhibited significantly higher bone healing in rat calvarial defects compared 
to hydrogels without MMP-sensitivity as well as those without BMP2. Further work has 
even   shown that MMP-sensitive BMP2-loaded synthetic hydrogels exhibit higher bone 
regeneration in a critically-sized defect compared to the current clinical standard of a 
BMP2 loaded absorbable collagen sponge [125]. This biomaterial platform has also been 
used for vascularization applications through incorporation of angiogenic proteins [126, 
127]. Covalently conjugating VEGF onto a PEG-diacrylate matrix results in increased 





with VEGF in the media indicating the importance of controlled growth factor presentation 
[128]. In vivo, delivering VEGF through covalent tethering to a protease-degradable PEG-
maleimide matrix increases therapeutic re-vascularization in both hind limb ischemia and 
myocardial infarction models [129, 130]. Importantly, the VEGF-incorporated matrix 
increases the survival and function of transplanted islets thus showing promise for other 
cellular therapies [131].  
A conceptually different strategy but one that still relates to the controlled 
presentation of growth factors is that of tethering heparin or other growth factor binding 
domains onto implantable materials. A highly negatively charged sulfated molecule, 
heparin exhibits the ability to bind to numerous angiogenic and osteogenic growth factors 
including VEGF, FGF, PDGF, and BMP2 through their heparin-binding domains. 
Scaffolds containing the covalently-bound heparin attempt to mimic the ECM by 
controlling the presentation and activity of growth factors through an affinity-based system 
[132, 133]. Heparin-bound BMP2 has been shown to induce elevated levels of ALP activity 
and increase proliferation in C2C12s compared to soluble BMP2 [134].  Taking a step 
further, certain materials can be chemically sulfated in order to bind to growth factors with 
the same or even higher affinity as heparin itself with sulfated alginate exhibiting enhanced 
FGF2-mediated vasculogenesis in vivo [135].  In lieu of heparin, Hubbell’s group has 
pioneered the use of short protein fragments having precisely controlled cell and growth 
factor binding sites. By engineering a recombinant fibronectin fragment to contain fibrin-





demonstrated that delivery of this fragment within a fibrin construct along with nominal 
levels of BMP2 and PDGF-BB significantly increased bone healing in a rat calvarial defect 
compared to fibrin constructs lacking the protein fragment [65]. Additionally, delivering 
VEGF and PDGF-BB within fragment-functionalized fibrin matrices enhanced skin wound 
healing in diabetic mice through increased angiogenesis. Further work in this area has 
resulted in isolation of a domain found on placenta growth-factor-2 that binds strongly to 
ECM proteins [136]. Inclusion of this domain onto VEGF, PDGF-BB, and BMP2 resulted 
in increased angiogenesis in an induced murine skin wound as well as elevated bone 
healing in a calvarial defect. 
In addition to tissue-demanded kinetics control, covalently or affinity-based 
tethering of growth factors can potentially increase their half-lives compared to their 
unconjugated form, although this is system-dependent on the site of immobilization and 
the ability for interactions to still exist with specific epitopes [137-139]. To date however, 
no study has investigated materials in which controlled, tissue-demanded release of 
angiogenic growth factors have been applied in the context of bone regeneration leaving 
the field open to further materials engineering. 
2.2.4.2 Role of biomaterials in enhancing MSC efficacy: Integrins 
As stated earlier, integrins can profoundly affect cell phenotype based on the 
downstream pathways that are activated following integrin binding to the ECM. 





downstream pathways [140]. MSCs, for example, have been observed to undergo enhanced 
osteogenic differentiation upon binding and activation of the α2β1 integrin that binds to 
type I collagen [141]. Because of this, biomaterial scaffolds have been engineered to 
activate only a certain repertoire of integrins in the hopes of being able to control cell 
phenotype. Importantly, a concerted effort has been placed on identifying and recognizing 
minimal integrin binding motifs on large ECM proteins to allow for modification of 
surfaces for cell-binding. In 1984, Pierschblacher and Ruoslahti first discovered the amino-
acid sequence RGD as a minimal binding domain on fibronectin and postulated its presence 
in other proteins [142]. Since then, multiple other peptide sequences derived from proteins 
have been identified as binding domains such as the peptide sequences termed ‘GFOGER’ 
and ‘IKVAV’ for collagen and laminin respectively [143-145]. Specifically for bone, 
Wojtowcz et al. demonstrated that when the α2β1-binding peptide GFOGER is coated on 
polycaprolactone (PCL) scaffolds and implanted into a critical-size defect in rat femurs, 
the coated scaffolds elicited enhanced bone regeneration compared to both non-coated 
scaffolds and empty controls [146]. Integrin-functionality has also been explored for use 
in vascularization. Endothelial cells undergoing angiogenesis abundantly express the αvβ3 
integrin and treatment with an αvβ3 blocking antibody has been shown to abrogate tumor 
vascularization in small animal models [147, 148]. The successful use of integrin-blocking 
antibodies for inhibiting tumor vascularization and tumor growth in small animal models 
paved the way for integrin-blocking antibodies to be used in several clinical trials although 





been placed on limiting vascularization through blocking integrins, little to no attention has 
been paid to augmenting vascularization for tissue regeneration purposes through integrin 
strategies. Specifically for vascularization, the VEGF receptor, VEGFR-2, and the β3 
exhibit a type of synergism in which VEGFR-2 activation induces β3 phosphorylation 
which consequently induces VEGFR-2 phosphorylation and activation of downstream 
angiogenic signalling [151]. Utilization of this synergism by providing a material that has 
both VEGF as well as is functionalized to bind preferentially to the β3 integrin subunit 
could function as a potential vascularization strategy.   
2.3 Mesenchymal stem cells for immunomodulation 
As stated earlier, hMSCs have two general groups of properties: 1) These cells 
exhibit the ability to differentiate down osteogenic, chondrogenic and adipogenic lineages, 
but have also been claimed to differentiate into other cell types including muscle and 
endothelial lineages [3, 152-154] and 2) hMSCs secrete a repertoire of factors distinct from 
other cells and that has been noted to aid in inducing a pro-resolution phase after 
inflammation or injury [155]. Initial work with MSCs noted that MSCs had the capacity to 
repair damaged or destroyed tissue notably in bone. Because of their differentiation 
potential, there was debate that this could be a result of direct differentiation of the cells 
into osteoblasts which would then regenerate the bone. In a 2005 study, Taguchi and 
colleagues induced femur fractures in mice followed by an infusion of GFP-labelled bone 





osteocalcin-dual positive cells within the callus and hypothesized that the infused bone 
marrow cells directly differentiated into osteoblasts within the defect thus contributing to 
its regeneration [156]. More recently however, mounting evidence points to a more indirect 
process of MSC-based tissue regeneration where these cells act as a modulatory player 
throughout the inflammatory and restorative process. In this section, we will discuss three 
topics regarding MSC-immunomodulation: 1) what properties do MSCs exhibit and how 
are they pertinent to immunomodulation, 2) chronic inflammatory and auto-immune 
disease models in which MSCs have been employed, and 3) issues with current approaches 
and how can new technologies alleviate these issues.    
2.3.1 Properties of MSCs for immunomodulation 
Properties of MSCs for immunomodulation can be separated into two broad 
categories: 1) the secretion of soluble factors and 2) contact-dependent factors. MSCs 
secrete a repertoire of soluble factors that are involved in immunomodulation including 
interleukin-6 (IL-6), prostaglandin E2 (PGE2), indoleamine-pyrrole 2,3-dioxygenase 
(IDO), transforming growth factor-β (TGF-β), IL-10, VEGF, M-CSF as well as a variety 
of CCLs and CXCLs [157-159].  
2.3.1.1 Soluble factors: Indoleamine-pyrrole 2,3-dioxygenase (IDO) 
Indoleamine-pyrrole 2,3-dioxygenase (IDO) is an enzyme that constitutes the rate-





IDO and its role in modulation of immune cells discovered that select subsets of antigen-
presenting cells (APCs) express IDO and have significant immunomodulatory effects on 
T-cells [162]. Dendritic cells and macrophages that co-express CD123 and CCR6 have 
enhanced IDO activity which correlates with reduction in T-cell proliferation in vitro [163]. 
Multiple groups have since affirmed that MSCs also express IDO under certain conditions 
and that MSC-secreted IDO expression is correlated with reductions in activated T-cell 
proliferation when MSCs are co-cultured with activated T-cells [164-166]. Moreover, this 
suppression of proliferation is at least in part due to MSC-secreted IDO activity as addition 
of an IDO inhibitor restores proliferation of the treated T-cells [164, 167]. MSC-based IDO 
also plays a role in the regulation of natural killer (NK) cells. When MSCs were co-cultured 
with isolated NK cells, the proliferation and cytotoxicity of the NK cells was significantly 
reduced while addition of an IDO inhibitor partially restored NK activity [168]. 
Interestingly, previous studies have argued that IDO is in fact not important for MSC-based 
immunomodulation, instead arguing that it is inducible nitric oxide synthase (iNOS). Ren 
et al. treated MSCs with an IDO inhibitor and found no effect on splenocyte proliferation 
while iNOS activity did correlate with lower T-cell proliferation with Sato and colleagues 
affirming this as well [169, 170]. Further elucidation into this paradox revealed species 
differences in immunomodulation with mouse MSCs utilizing iNOS and human MSCs 
using IDO to suppress immune responses [171]. This ‘devil in the details’ underscores the 
risk in drawing conclusions from dissimilar studies as well as the importance of utilizing 





activity, the cells must first be activated by the presence of pro-inflammatory factors, the 
most important being interferon gamma (IFN-γ) [172]. The process of activating MSCs to 
express IDO through incubation with IFN-γ is known as ‘licensing’ [173]. While activated 
T-cells and other immune cells secrete IFN-γ to then activate MSCs, licensing MSCs with 
IFN-γ prior to co-culturing with immune cells enhances the MSC’s immunosuppressive 
activities by not only blocking T-cell proliferation, as un-licensed MSCs do, but also 
ameliorating T-cells’ effector functions [174]. Furthermore, IDO activity within MSCs is 
significantly different among different MSC donors, thus implicating a need for 
augmenting IDO activity to ensure a higher portion of MSC batches can elicit a biological 
effect [175].  
2.3.1.2 Soluble factors: Prostaglandin E2 
Prostaglandin E2 (PGE2) is a small-molecule product of the metabolism of 
arachidonic acid by cyclooxygenases, COX-1 and COX-2 [176]. While COX-1 is 
constitutively expressed, COX-2 expression is highly dynamic with increased expression 
occurring via concerted actions of specific cytokines and growth factors within pro-
inflammatory environments [177]. While COX-2 can significantly increase presence of 
PGE2 in inflammatory environments, the degradation of PGE2 is also tightly controlled by 
two metabolic enzymes 15-hydroxyprostaglandin dehydrogenase and 15-keto-
prostaglandin-13-reductase [178]. PGE2 has a short half-life in vivo, approximately seven 





based on the activity of both COX-2 as well as the two metabolic enzymes governing its 
degradation [179]. PGE2 exerts its effect through an array of G-protein coupled receptors 
designated EP1, EP2, EP3 and EP4 receptors which subsequently activate cAMP, PI3K, 
and Rho downstream pathways depending on which EP receptor is activated [180]. 
Regarding its role in MSC-related immunosuppression, PGE2 has been implicated in a 
similar role as that of IDO. When licensed with IFN-γ, hMSCs significantly increase their 
secretion of PGE2 [181, 182]. T-cells cultured without MSCs but with increasing 
concentrations of exogenously added PGE2 exhibit a dose-dependent decrease in their 
proliferation similar to that of when MSCs are placed in co-culture [181]. In addition to 
having the ability to suppress T-cell proliferation, MSC-secreted PGE2 is also implicated 
in inducing a CD4+Foxp3- regulatory T-cell phenotype while inhibiting a T-helper 17 cell 
differentiation [183, 184]. The effect of MSCs on NK cells, as discussed earlier being at 
least partially affected by IDO, is also dependent on PGE2 as treatment with a COX-2 
inhibitor restores NK cell proliferation and effector function [185]. An effect of PGE2 not 
noted for IDO is the inhibition of dendritic cell differentiation from monocytes [186]. 
When co-cultured with MSCs, human-derived monocytes in dendritic cell differentiation 
media show significantly less dendritic cell differentiation compared to monocytes cultured 
without MSCs. Furthermore, when the co-cultures were treated with a COX-2 inhibitor, 
the dendritic cell differentiation is restored even in the presence of MSCs [186]. A common 
theme that can be seen here and repeated throughout this section is the multitude of MSC-





2.3.1.3 Soluble factors: IL-6 
Interleukin-6 is a pleiotropic cytokine secreted by a variety of cells including 
MSCs. While MSCs secrete basal levels of IL-6, this secretion is, similar to PGE2 and 
IDO, increased when pro-inflammatory cytokines are present in the MSC 
microenvironment [187]. Similar to PGE2, IL-6 has been implicated in the inhibition of 
monocyte-derived dendritic cell differentiation [188]. When MSCs were incubated with 
purified monocytes under dendritic cell differentiation conditions, as seen in other studies, 
the differentiation of monocytes was prevented as analyzed through the ratio of CD1a+ to 
CD14+ markers. When an anti-IL-6 neutralizing antibody was added however, the 
differentiation of dendritic cells was partially restored [188]. Further studies concluded that 
this MSC-secreted IL-6 effect also holds for CD34+-derived dendritic cell differentiation 
[189]. M-CSF was also implicated in these same studies as an important factor in inhibiting 
dendritic cell differentiation [188, 189]. A proposed mechanism for this effect is that the 
IL-6 secreted by MSCs induces monocytes to upregulate the secretion of IL-10 which in 
turn acts in an autocrine fashion to halt the dendritic cell differentiation process [190]. 
2.3.1.4 Soluble factors: Macrophage colony stimulating factor (M-CSF) 
Macrophage colony stimulating factor (M-CSF) is a cytokine constitutively 
expressed by a variety of cells in the body including MSCs [191]. M-CSF is commonly 
used to differentiate bone marrow cells into macrophages eliciting an anti-inflammatory 





cytokine IL-10 as well as CCL2 compared to macrophages cultured in granulocyte 
macrophage colony-stimulating factor which tend to elicit a more inflammatory phenotype 
[193]. Because of this, MSC-secreted M-CSF secretion has been studied as a conduit for 
its role in immunosuppression. As stated earlier, groups that concluded IL-6 to have an 
important factor in regulating the differentiation of monocytes to dendritic cells also found 
M-CSF to have a similar effect as well [188, 189]. When MSC / monocyte co-cultures were 
treated with a neutralizing antibody toward M-CSF, monocytes partially regained their 
differentiation potential toward dendritic cells. Importantly, neutralizing both IL-6 and M-
CSF allowed monocytes to regain their differentiation potential to a greater extent than 
neutralizing either factor individually. On a related note, MSC-secreted M-CSF plays a 
crucial role in the ability for MSCs support hematopoiesis in vitro [194].  
2.3.1.5 Soluble factors: CCL2 / Monocyte chemoattractant protein -1 
CCL2, otherwise known as monocyte chemoattractant protein-1, is also a cytokine 
secreted by MSCs and implicated in their role of immunomodulation. MSC-secreted CCL2 
has been shown to inhibit immunoglobulin production from differentiated B cells in both 
in vitro and in vivo models [195].  
2.3.1.6 Contact-dependent factors: PD-L1 (B7-H1) 
In addition to the various soluble cytokines that have been implicated to play a role 





have been studied and proposed to enhance the anti-inflammatory phenotype of MSCs. 
This was first identified in vitro when transwells were used to separate MSC culture from 
the T-cells. While MSCs on transwells still retained their ability to suppress activated T-
cell proliferation, it was significantly less potent than cells in direct contact with the T-cells 
[196, 197]. One of the hypothesis following this finding was that the soluble factors 
necessary for immunosuppression, namely nitric oxide, had short half-lives and thus 
needed to be in close proximity to the immune cells [170]. However, when it was 
discovered that nitric oxide was used by mouse MSCs rather than human MSCs and the 
transwell effect was still noted in human MSCs, this hypothesis was partially ruled out. A 
recent study noted that MSCs regulate T-cell suppression through IDO-independent 
pathways, notably through cell-cell contact and the programmed death pathway [198]. 
MSCs express high levels of membrane-bound B7-H1 molecule otherwise known as 
programmed death ligand-1 (PD-L1) when licensed with IFN-γ. When these licensed 
MSCs are co-cultured directly with T-cells and siRNA directed at PD-L1, the MSC-based 
immunosuppression of T-cell proliferation is significantly reduced [198]. Future 
experiments showed that this regulation by B7-H1 is independent of the IDO pathway as 
inhibiting IDO activity had no effect on the cell-cell contact inhibition. Together, the 
presence of both soluble and cell-cell contact mediated pathways as well as the multitude 
of independent pathways for MSC-based immunomodulation contributed to the notion of 
MSCs being a useful tool for treatment of chronic and autoimmune diseases. 





Because of their role in immunomodulation, MSCs have been proposed as a 
candidate for cell therapy in a variety of preclinical disease models including colitis, graft 
vs host disease (GvHD), arthritis, autoimmune encephalomyelitis, type 1 diabetes, lupus 
and many more [169, 199-204]. Of particular note however are the disease models in which 
a number of clinical trials have and are being conducted to ascertain the efficacy of MSC 
therapy, notably acute GvHD and inflammatory bowel disease (IBD).  
Acute Graft vs Host Disease (aGvHD) is a condition following hematopoietic stem 
cell transplantation (HSCT) where donor T-cells become activated by the host system due 
to the preparative regime and begin damaging host tissue, usually within the 
gastrointestinal tract, the skin and liver [205]. Following allogenic HSCT, up to 14% of 
recipients will develop severe aGvHD with a third of these patients not responding to 
steroid therapy leading to a dismal prognosis for survival [206]. MSCs have been proposed 
as a way to treat steroid-resistant aGvHD with over 30 studies either completed or 
underway (www.clinicaltrials.gov).  Le Blanc and colleagues found that out of 55 patients 
having severe aGvHD that received an infusion of MSCs, 30 had a complete response while 
the other 25 had either a partial or no response to MSC therapy [207]. Those that did not 
respond had a mortality rate of 72% within the first year after treatment. The complete 
responders had a lower mortality rate but of the 30 that responded, 11 had died within the 
first year from transplantation-related issues [207]. Another clinical study by Resnick and 
colleagues found similar results in which responders to MSC infusion therapy had a 





[208]. However, only 17 of 50 patients showed a complete response with the rest showing 
either partial or no response. These and other trials show a similar pattern in that the 
fraction of patients exhibiting a complete response, while exhibiting much higher survival 
rates, is approximately half of total patients receiving therapy [209].  Other trials 
meanwhile cast doubt on the efficacy of MSCs to treat aGvHD altogether. A phase III 
clinical trial for using MSCs for treatment of steroid-refractory GvHD failed to meet an 
overall response rate better than placebo control [210]. We will discuss some of the 
important issues and paradoxes in MSC efficacy following the discussion on IBD. 
 MSC-based therapy in clinical trials have also been used for treating IBD. IBD, 
including Crohn’s disease and ulcerative colitis, is an autoimmune disease where 
overactive T-cells within the intestine react with surrounding tissue ultimately leading to 
excessive inflammation and damage causing detrimental effects on quality of life [211, 
212]. To date, 22 clinical trials using MSCs as a treatment for Crohn’s disease are either 
completed or ongoing with results similar to that of GvHD, notably, that while MSC 
therapy can improve patient outcome, only a limited portion of patients respond to the 
therapy (www.clinicaltrials.gov). In a phase I clinical study, out of 9 patients exhibiting 
refractory Crohn’s disease and given two doses of MSC therapy, 3 patients showed positive 
response to the treatment while another three needed surgery due to disease progression 
[213]. In another phase II clinical study, out of 15 patients exhibiting refractory Crohn’s 
disease, although the overall disease score was significantly reduced with administration 





patients [214]. In a phase III randomised double-blind clinical trial, Panés and colleagues 
found that out of 107 patients receiving MSC infusion therapy to treat their refractory 
Crohn’s disease, 53 patients achieved remission compared to 36 out of 105 patients in the 
placebo group [215]. Overall, as was seen in the GvHD cases, treatment with MSCs seems 
to enhance patient outcome but only in a portion of the total patient group, in some cases 
less than half. The cause of this can be traced to one of two factors: 1) patient factors or 2) 
treatment factors. While patient factors are vitally important and much research is being 
conducted on ascertaining which patients might be most beneficial for which therapies, we 
will limit our discussion to treatment-related factors and point out how these can be 
enhanced with recent research advances.  
2.3.3 Augmenting treatment-related factors for enhanced patient outcomes 
Whereas other factors are certainly in play, one of the main factors that can affect the 
efficacy of cell therapy is the state in which the cells that are infused are at. In other words, 
the efficacy of cell therapy relies on the ability of the infused cells to impart a desired 
effect. In terms of immunomodulation, this translates into increasing the anti-inflammatory 
nature of MSCs. As stated earlier, one of the ways MSCs show enhanced 
immunomodulation in vitro is through licensing and this notion continues for preclinical 
studies. Polchert et al. found that mice exhibiting GvHD injected with MSCs pre-treated 
with IFN-γ showed significant improvements in GvHD scores compared to those injected 





where MSCs stimulated to augment IDO activity prior to injection showed enhanced 
efficacy in mice compared to MSCs that were not pre-stimulated [217, 218]. Another 
potential issue with the anomalies posed by the mixed clinical trial results is potentially in 
the heterogeneity of the cell sources itself. Donor variability and the immunomodulatory 
capacity of MSCs from different sources are known to exist [175]. A recent study however 
shows that while differences were seen at basal states in between different MSC batches, 
once the cells were licensed with inflammatory factors, all cells elevated their immune 
inhibitory capacities to similar levels [219]. 
MSCs that are licensed prior to use in vivo thus show signs of higher efficacy than those 
that are not. However, two issues arise with this approach: 1) the length of activation and 
2) the complexity of clinical translation. In terms of the former, while licensing MSCs 
increases their immunomodulatory capabilities, once MSCs are removed from an 
environment presenting IFN-γ, their immunomodulatory capability decreases significantly 
[220]. To alleviate this issue, various groups have attempted to continuously license MSCs 
through either genetic modification or continuous presentation of IFN-γ within a 
biomaterial [220, 221]. Approaches focused on continuous presentation of IFN-γ though 
do not currently control the release of IFN-γ thus posing a risk for use in vivo to potentially 
augmenting the deleterious effect of additional IFN-γ. Furthermore, genetic modification 
of MSCs faces significant translation and regulatory barriers. In terms of the second issue, 
that of complexity of clinical translation, the act of needing to culture cells ex vivo for 





a biomaterial scaffold that can continuously present encapsulated MSCs with a licensing 
agent in a controlled fashion can eliminate the need to culture cells ex vivo, improve the 
clinical translatability of MSC therapy and augment MSC efficacy for improved patient 






* chosen as 2016 Student Award for Outstanding Research by Society for Biomaterials 
CHAPTER 3. AIM 1: INTEGRIN-SPECIFIC HYDROGELS 
FUNCTIONALIZED WITH VEGF FOR VASCULARIZATION 
AND BONE REGENERATION 
Adapted from:  
Garcia JR, Clark AY, Garcia AJ. Integrin-specific hydrogels functionalized with VEGF 
for vascularization and bone regeneration in critical-size bone defects. J. Biomedical 
Materials Research A. 2016. 104(4): 889-900  [222]* 
3.1 Abstract: 
Vascularization of bone defects is considered a crucial component to the successful 
regeneration of large bone defects. Although vascular endothelial growth factor (VEGF) 
has been delivered to critical-size bone defect models to augment blood vessel infiltration 
into the defect area, its potential to increase bone repair remains ambiguous. In this study, 
we investigated whether integrin-specific biomaterials modulate the effects of VEGF on 
bone regeneration. We engineered protease-degradable, VEGF-loaded polyethylene glycol 
(PEG) hydrogels functionalized with either a triple-helical, α2β1 integrin-specific peptide 
(GFOGER) or an αvβ3 integrin-targeting peptide (RGD). Covalent incorporation of VEGF 
into the PEG hydrogel allowed for protease degradation-dependent release of the protein 





the murine radius, GFOGER-functionalized VEGF-free hydrogels exhibited significantly 
increased vascular volume and density and resulted in a larger number of thicker blood 
vessels compared to RGD-functionalized VEGF-free hydrogels. VEGF-loaded RGD 
hydrogels increased vascularization compared to VEGF-free RGD hydrogels, but the 
levels of vascularization for these VEGF-containing RGD hydrogels were similar to those 
of VEGF-free GFOGER hydrogels. VEGF transiently increased bone regeneration in RGD 
hydrogels but had no effect at later time points. In GFOGER hydrogels, VEGF did not 
show an effect on bone regeneration. However, VEGF-free GFOGER hydrogels resulted 
in increased bone regeneration compared to VEGF-free RGD hydrogels. These findings 
demonstrate the importance of integrin-specificity in engineering constructs for 
vascularization and associated bone regeneration.  
3.2 Introduction: 
Vascularization is a crucial factor in bone development as well as the repair of bone 
defects [11, 223, 224]. In the developing skeleton, long bones are formed through 
endochondral ossification which involves the invasion and sprouting of blood vessels into 
the intermediate cartilage tissue followed by osteoprogenitor cell migration and 
mineralization of the cartilaginous anlage [30]. Blocking infiltration of blood vessels into 
the cartilage tissue causes enlarged hypertrophic zones associated with incomplete and 
delayed onset of ossification and suboptimal bone formation [225]. In terms of bone repair, 





and impaired healing [226]. Co-induction of a tibial fracture and vascular injury in the form 
of hind limb ischemia in a mouse model increases the chances of a non-union compared to 
the fracture alone [55]. Anti-angiogenic treatment to inhibit the initial revascularization 
response following a critical-size segmental defect also results in lower levels of bone 
formation and a higher prevalence of non-union [117]. Although current gold-standards of 
autografts and allografts are extensively used in the clinic, these constructs are significantly 
limited by donor-site morbidity, supply, bioactivity and risk of infection [227]. 
Additionally, the revascularization of these grafts remains limited without micro-surgical 
procedures which often results in high degrees of local tissue morbidity [228, 229]. 
Therefore, incorporating cues to augment the vascularization response can greatly enhance 
the efficacy of these treatments while diminishing their limitations. 
Vascular endothelial growth factor (VEGF) has routinely been delivered to increase 
vascularization in vivo. By interacting with two main tyrosine kinase receptors, VEGFR1 
and VEGFR2, VEGF destabilizes existing blood vessel walls and allows endothelial cells 
to proliferate and migrate in the direction of highest VEGF concentration [116]. VEGF is 
instrumental in bone development as blocking VEGF activity results in reduced 
angiogenesis, massive chondrocyte death and severely under-developed bone [34, 35]. 
However, in terms of bone repair, the efficacy of exogenous VEGF in increasing 
vascularization and associated bone regeneration remains ambiguous. One of the first 
studies utilizing VEGF for bone treatment demonstrated that continuous delivery of VEGF 





in increased bone formation compared to no VEGF treatment [117]. Subsequent efforts 
have focused on engineering scaffolds to deliver VEGF through more practical 
methodologies. VEGF incorporated into β-tricalcium phosphate and PLGA scaffolds 
increased blood vessel invasion and bone formation in critical-size defects [120, 121]. 
Other reports, however, have shown VEGF to induce minimal bone formation despite 
enhanced blood vessel formation [230-234]. 
 Synergistic interactions between VEGF receptors and integrin adhesion receptors 
provide signals regulating vascularization. For example, blocking antibodies against the α2 
subunit of the collagen-binding α2β1 integrin inhibits VEGF-dependent endothelial cell 
chemotaxis [235]. Consistent with these results, deletion of the β1 integrin subunit using 
the Cre-lox system negatively impacts angiogenic sprouting [235]. VEGF has also been 
shown to upregulate endothelial cell surface expression of α2β1 [236]. In addition to the 
α2β1 integrin, the αvβ3 integrin plays a central role in angiogenesis and vascularization [147, 
237, 238]. 
While the mechanism of integrin-dependent angiogenesis remains unclear, antagonists 
to αvβ3 have been used to prevent abnormally active angiogenesis within tumors as 
activated endothelium within these environments exhibit greatly enhanced expression of 
αvβ3 [239-243]. Extensive cross-talk also exists between αvβ3 and VEGF as expression of 





with phosphorylated p66 Shc [106]. The β3 subunit is also involved in the activation of 
VEGFR2 in response to VEGF [105, 151].  
Because of the interplay between VEGF and integrins α2β1 and αvβ3, the objective of 
this study was to investigate whether presentation of integrin-specific peptides within a 
hydrogel in combination with exogenous VEGF modulates vascularization and bone 
formation in a murine segmental bone defect model. We synthesized protease-degradable 
poly(ethylene glycol)-based hydrogels functionalized with VEGF and either the collagen 
I-mimetic α2β1-targeting GFOGER peptide or the fibronectin-derived αvβ3-targeting RGD 
peptide. We then implanted these constructs within critical-size murine radial bone defects 
and evaluated blood vessel formation and newly formed bone tissue. Based on previous 
studies showing that GFOGER-functionalized biomaterials promote osteoblastic 
differentiation in vitro [244] and enhance osseointegration of metal implants in rat tibiae 
[245], we hypothesized that VEGF-functionalized GFOGER hydrogels would increase 
vascularization and subsequent bone regeneration compared to VEGF-functionalized RGD 
hydrogels. 
3.3 Materials and Methods: 
3.3.1 PEG hydrogel synthesis and VEGF release kinetics 
Four-arm maleimide-end functionalized PEG macromer (PEG-MAL 20 kDa MW, 





(Invitrogen) for 15 min at room temperature in 10 mM HEPES buffer pH=7.4 followed by 
functionalization with either GFOGER peptide, GGYGGGP(GPP)5GFOGER(GPP)5GPC 
(AAPPTec), or RGD peptide (GRGDSPC) (AAPPTec). Functionalized macromers were 
cross-linked using the bi-cysteine peptide VPM (GCRDVPMSMRGGDRCG) 
(AAPPTec). The PEG-MAL hydrogels were synthesized to obtain a final concentration of 
1.0 mM adhesive peptide and 10 µg/mL VEGF unless otherwise noted. The concentration 
of cross-linker used for the synthesis of each hydrogel was calculated by matching the 
number of cysteine residues on the cross-linker to the number of residual maleimides on 
the PEG-MAL macromer following adhesive peptide and VEGF functionalization. 
Hydrogels were allowed to gel at 37°C for 15 min before swelling in PBS. For verification 
of VEGF tethering to the PEG-MAL macromer, the VEGF-PEG-MAL product was run on 
SDS-PAGE gel followed by protein visualization with Sypro Red (Life Technologies) 
staining.  
To assess VEGF release kinetics, VEGF was labelled with NHS-AlexaFluor 488 (Life 
Technologies), purified, and incorporated into hydrogels as described. Hydrogels were 
incubated in either PBS or 50 µg/mL collagenase (Worthington Biomedical). At specified 
time points, supernatant was collected and analyzed for fluorescence.  
3.3.2 Rheology 
To examine the effect of adhesive peptide and VEGF incorporation on the rheological 





oscillatory strain and frequency sweeps performed on a MCR 302 stress-controlled 
rheometer (Anton Paar, Austria) with a 9 mm diameter, 2° cone and plate geometry. The 
hydrogels were synthesized as described and loaded between the cone and plate, after 
which the measuring system was lowered to a 39 µm gap. Initial strain amplitude sweeps 
were performed at an angular frequency of 10 rad s-1 to determine the linear viscoelastic 
range of the hydrogel. Oscillatory frequency sweeps were then used to examine the storage 
and loss moduli (ω= 0.5-100 rad s-1) at a strain of 1%. 
3.3.3 Bioactivity of PEGylated VEGF 
Human umbilical vein endothelial cells (HUVECs, Lonza) were grown in complete 
endothelial growth media EGM-2 (Lonza). Cells were synchronized in growth factor-free 
basal media (EBM-2, Lonza) with 1% fetal bovine serum (FBS) for 8 hours followed by 
addition of soluble VEGF, VEGF-conjugated PEG-MAL macromer, or control (VEGF-
free) media for 48 hr. Cell metabolic activity was measured using CellTiter 96 AQueous 
One Solution Cell Proliferation Assay (Promega). To assess the activity of endothelial cells 
on VEGF-functionalized hydrogels, GFOGER-modified hydrogels were synthesized with 
or without incorporated VEGF. HUVECs were seeded at 10,000 cells/cm2 and incubated 
for 4, 8 or 15 hours. Samples were fixed in 3.7% paraformaldehyde, stained with 
AlexaFluor 488-conjugated phalloidin and DAPI, and imaged on a Nikon C2 confocal 
microscope. Endothelial cell network length and cell numbers were quantified using a 





3.3.4 3D endothelial cell network formation 
To study 3D endothelial cell network assembly, a co-culture of GFP-expressing 
HUVECs (Angioproteomie) and mouse embryo 10T1/2 cells (ATCC) was used. GFP-
expressing HUVECs and 10T1/2 cells were resuspended in media and encapsulated in 
PEG-MAL hydrogels presenting either GFOGER or RGD at final cell densities of 4 x106 
cells/mL for 10T1/2 cells and 15 x106 cells/mL for HUVECs. For gels containing VEGF, 
gels were incubated in EGM-2 media without supplemented VEGF. For gels synthesized 
without VEGF, gels were incubated in EGM-2 media with or without soluble VEGF. The 
cell-laden hydrogels were cultured for 48 hours, rinsed, and fixed in 3.7% 
paraformaldehyde. GFP-expressing HUVECs were imaged on a Nikon C2 confocal 
microscope and 3D network formation analyzed using a custom ImageJ macro.  
3.3.5 Bone defect surgery 
A critical-size bone defect model in the mouse radius was used to evaluate bone 
formation as previously described [246]. All animal experiments were performed with the 
approval of the Georgia Tech Animal Care and Use Committee within the guidelines of 
the Guide for the Care and Use of Laboratory Animals. C57BL/6J wild-type male mice (8-
10 weeks old, Jackson Laboratories) were anesthetized under isoflurane and fur was 
removed from the right forelimb. Prior to surgery, mice were administered a single dose of 
slow-release buprenorphine for pain relief. The right forelimb was then swabbed with 





surrounding the ulna and radius was dissected away, and a 2.5 mm complete excision in 
the radius was made using a custom-built bone cutter. A 4-mm long polyimide sleeve with 
laser machined holes containing 3.0 µL of hydrogel was carefully inserted over the ends of 
the defect. The incision was then closed using Vicryl sutures. Mice were monitored post-
surgery for lethargy, weight loss, normal eating habits and signs of distress. 
3.3.6 µCT angiography 
Animals were euthanized by CO2 inhalation at 8 weeks post-surgery. Radiopaque 
contrast agent-enhanced µCT angiography was performed using a protocol modified from 
Phelps et al. [129]. Briefly, an incision was made across the lower abdomen of the mouse 
followed by a continuing incision up the midline of the mouse exposing the entire 
abdominal cavity. The thoracic cavity was cut to carefully expose the heart. A butterfly 
needle was inserted into the left ventricle followed by cutting of the lower vena cava. Mice 
were then sequentially perfused with saline, 10% neutral buffered formalin, saline and lead 
chromate-based radiopaque contrast agent at a 30:60:10 v/v mixture of MV-122 
Yellow:MV-diluent:MV curing agent (Microfil MV-122, Flow Tech). Samples were kept 
at 4°C overnight to allow the contrast agent to polymerize, and the forearms were then 
incubated for 72 hours in Krajian decalcification solution (Ricca Chemical), rinsed with 







Following euthanasia by CO2 inhalation, the ulna and radius were excised and fixed in 10% 
neutral-buffered formalin, decalcified using Krajian decalcification solution, processed for 
paraffin embedding and embedded in paraffin wax. Sections (5 µm thick) were 
deparaffanized and incubated in antigen retrieval solution (10 mM sodium citrate buffer, 
pH=6.0) overnight at 60°C. Sections were then stained with either rabbit anti-endomucin 
or rat anti-CD31 antibodies overnight at 4°C followed by secondary staining with 
AlexaFluor 488- and AlexaFluor 555-conjugated goat antibodies for 1 hour at room 
temperature. Sections were imaged on a Nikon C2 confocal microscope. 
3.3.8 VEGF & FGF-2 secretion 
Human mesenchymal stem cells (hMSCs, Texas A&M University) were grown in α-
MEM containing 16% FBS, 2 mM L-glutamine, 100 U/mL penicillin and 100 µg/mL 
streptomycin. HMSCs were encapsulated in VEGF-free integrin-specific hydrogels as 
previously described at a concentration of 5 x106 cells/mL and cultured for 24 hours in 
growth media. After 24 hours, the media was exchanged for osteogenic media (growth 
media with 10 nM dexamethasone, 20 mM Na-β-glycerolphosphate, and 50 µM L-ascorbic 
acid 2-phosphate). After 7 days in culture, the conditioned media was collected and assayed 
for VEGF and FGF-2 levels using ELISA (Life Technologies, USA). 





In vivo µCT imaging was performed on anesthetized mice using a VivaCT imaging 
system (Scanco Medical) at a voltage of 55 kVp and a current of 142 µA. Mice were 
centered such that the 2.5 mm radial defect was scanned within a 3.2 mm scan length 
window. Bone volume was evaluated as previously described [246]. Briefly, 2D slices were 
contoured to solely include the radius followed by application of a Gaussian filter 
(sigma=1, support=1, threshold= 540 mg HA/ccm). While 3D reconstructions displayed 
the full 3.2 mm scanned length, only the middle 2.0 mm of the defect was analyzed for 
bone volume.  
3.3.10 Statistics 
Error bars on graphs represent SEM. Comparisons among multiple groups was 
performed by one-way analysis of variance (ANOVA) with post-hoc Tukey tests. 
Comparisons between two groups were done through a t-test in GraphPad Prism 6. A p 
value of <0.05 was considered significant. 
3.4 Results 
3.4.1 Synthesis and characterization of VEGF-releasing PEG-MAL hydrogels 
We engineered hydrogels based on a maleimide-functionalized 4-arm PEG macromer 
which allows for peptide tethering onto the polymer precursor via a Michael-type addition 
reaction between the terminal-maleimide group and free thiols present on the biomolecules. 





cleavage site resulted in the formation of an insoluble cross-linked PEG hydrogel network 
sensitive to protease degradation (Fig. 2A). Prior to cross-linking, the PEG-MAL 
macromer was functionalized with VEGF. The VEGF-functionalized macromer was 
further reacted with either the RGD or GFOGER cell adhesion peptides in order to 
investigate the coupled effects of biomaterials-based VEGF delivery and integrin-
specificity on vascularization and bone regeneration. By design, covalent incorporation of 
VEGF onto the hydrogel backbone provides for cell-demanded release of VEGF as the 
construct degrades and the surrounding tissue invades. Covalent tethering of VEGF to the 
PEG-MAL macromer was verified through an expected increase in molecular weight for 
VEGF reacted with PEG-MAL polymer on SDS-PAGE (Fig. 2B).  
To determine the kinetics of VEGF release from integrin-specific hydrogels in vitro, 
VEGF was fluorescently labelled and incorporated into RGD- or GFOGER-functionalized 
hydrogels. Hydrogels subjected to collagenase treatment degraded within the first 48 hours 
and released 100% of the incorporated VEGF (Fig. 2C). We note that the collagenase 
concentration used was selected to fully degrade the gel by 2-3 days and does not reflect 
in vivo protease-dependent degradation [246, 247]. In contrast, hydrogels incubated in PBS 
remained intact and, following an initial burst release due to hydrogel swelling, retained 
approximately 70% of the loaded VEGF over a period of 5 days. To investigate whether 
adhesive peptide or VEGF incorporation influences the hydrogel’s mechanical properties, 
we performed dynamic oscillatory rheological testing to assess the storage (G’) and loss 





differences in moduli were detected among the hydrogel conditions tested (average storage 







Figure 2: Protease-degradable integrin-specific PEG-MAL hydrogels for degradation-
dependent release of covalently-tethered VEGF. (A) Schematic detailing PEG-MAL 
synthesis, stoichiometric ligand functionalization and growth factor incorporation. (B)  Gel 
electrophoresis of VEGF and PEG-MAL+VEGF demonstrating increased MW of VEGF 
tethered onto PEG-MAL macromer. (C) VEGF release profile from integrin-specific 
hydrogels treated in PBS or collagenase as measured through fluorescence (Mean ± SEM 
N=4). (D) Rheological properties of integrin-specific hydrogels measured through storage 
and loss moduli from dynamic oscillatory frequency tests (Box-whisker plot show min-











3.4.2 Bioactivity of PEGylated and hydrogel-tethered VEGF 
We next investigated the bioactivity of VEGF tethered to the PEG-MAL macromer. 
HUVECs cultured in media containing either PEG-MAL-conjugated or unmodified VEGF 
displayed similar dose-dependent responses in metabolic activity over the course of 48 
hours (Fig. 3A). This result indicates that VEGF tethered to the PEG-MAL macromer 
retains bioactivity and that the PEG macromer does not interfere with VEGF-dependent 
signaling.  
We further examined the bioactivity of VEGF tethered to hydrogels by assessing the 
proliferation and network formation of endothelial cells cultured on top of hydrogels with 
either VEGF-tethered or VEGF-free hydrogels. GFOGER-functionalized hydrogels 
supported cell adhesion regardless of VEGF incorporation (Fig. 3B).   By 8 and 15 hours 
after seeding, endothelial cells adhering to VEGF-containing hydrogels exhibited elevated 
levels of network formation compared to hydrogels lacking VEGF (Fig. 3B-C). By 
quantifying the number of nuclei, we also found a significant increase in the number of 
endothelial cells on VEGF-containing hydrogels compared to VEGF-free gels (Fig. 3D). 
Taken together, these results show that tethering VEGF to the PEG-MAL macromer either 
in soluble form or after incorporation into a hydrogel network maintains the bioactivity of 






Figure 3: Bioactivity of PEGylated VEGF. (A) Endothelial cell metabolic assay for VEGF 
vs. PEG-MAL-VEGF (Mean ± SEM n=6). (B) Images of endothelial cell networks on top 
of GFOGER-functionalized hydrogels either functionalized with (VEGF) or lacking VEGF 
(Control) over 15 hours (Scale bar = 200µm, DAPI=cyan, F-actin=magenta). (C) 
Quantification of endothelial cell network length measured through custom ImageJ macro. 







3.4.3 Integrin-dependent 3D endothelial cell tubulogenesis 
After confirming the biological activity of PEGylated VEGF, we examined the effect 
of different integrin ligands in conjunction with VEGF presentation on the vasculogenic 
response to these materials. We used a model for 3D vascular tubulogenesis consisting of 
GFP-expressing HUVECs encapsulated with 10T1/2 cells, which act as a supporting 
pericyte-like cell, in hydrogels functionalized with either the GFOGER or RGD adhesive 
peptide. For both adhesive peptides, endothelial cells encapsulated within VEGF-free 
hydrogels and cultured in VEGF-free media exhibited minimal tubulogenesis as the cells 
remained largely rounded and failed to form protrusions to adjacent cells (Fig. 4A). In 
contrast, endothelial cells cultured in the presence of soluble VEGF in the media showed 
increased network formation in both RGD and GFOGER hydrogels (Fig. 4B). Importantly, 
VEGF-containing hydrogels cultured in VEGF-free media displayed enhanced endothelial 
cell-based network formation compared to hydrogels in VEGF-free conditions for both 
RGD- and GFOGER-functionalized hydrogels (Fig. 4B). For GFOGER-functionalized 
hydrogels, VEGF containing hydrogels exhibited similar levels of increased network 
formation compared to that of GFOGER-functionalized hydrogels cultured in VEGF-
containing media. VEGF-containing RGD-functionalized hydrogels displayed elevated 
network formation compared to RGD hydrogels in VEGF-free conditions and RGD 
hydrogels cultured in media with VEGF (Fig. 4B). Taken together, the data demonstrates 





vitro compared to soluble VEGF present in the media. Furthermore, this increase in 







Figure 4: Integrin-specific hydrogels demonstrate VEGF-dependent increases in 3D 
endothelial cell network formation. (A) Projected Z-stack images of GFP-HUVECs 





conditions for 3 days (scale bar = 200 µm). (B) Quantification of 3D network length in 






3.4.4 VEGF-free GFOGER hydrogels enhances vascularization over VEGF-free RGD 
hydrogels 
We evaluated the potential of VEGF-functionalized hydrogels presenting integrin-
specific peptides to enhance vascularization in a murine critical-size radial bone defect 
model. We tested two different VEGF doses (50 and 250 ng, referred to as low and high 
doses, respectively) as well as hydrogels lacking VEGF (0 ng) for both RGD and 
GFOGER-functionalized hydrogels. Hydrogels of each condition were gelled within 
polyimide tube sleeves engineered with laser-machined holes to improve cell infiltration 
and nutrient transport across the sleeve walls. The hydrogel-containing sleeves were then 
implanted into 2.5 mm long unilateral murine radial defects and evaluated for vascular 
morphometric parameters within the bone defect area at 8 weeks via micro-computed 
tomographic (µCT) analysis of a perfused radiopaque polymer (Fig. 5A). Importantly, this 
technique measures functional vasculature connected to the host vasculature as the 
radiopaque polymer is perfused through the left ventricle and exits out the inferior vena 
cava to perfuse the vasculature. VEGF-free, RGD hydrogels exhibited very low levels of 
vascularization (Fig. 5A). With low and high doses of VEGF, RGD hydrogels exhibited 
significantly increased vessel number as well as significantly decreased vessel spacing 
denoting a higher density of vessels for both VEGF doses (Fig. 5C-D). Low doses of VEGF 
also significantly increased the total blood vessel volume and resulted in higher frequency 
of both small diameter (25-50 µm) and larger diameter vessels (80-100 µm) compared to 





Remarkably, VEGF-free GFOGER hydrogels displayed significantly increased 
vascularization across all quantified parameters (vessel volume, number and spacing) 
compared to VEGF-free RGD hydrogels (Fig. 5B-D). The levels of vascularization present 
within VEGF-free GFOGER hydrogels were equivalent to those of VEGF-containing RGD 
hydrogels. Furthermore, at high VEGF doses, while GFOGER and RGD hydrogels showed 
similar levels of vascular number and spacing, GFOGER hydrogels demonstrated elevated 
levels of total vascular volume compared to those of RGD hydrogels.  The high levels of 
vascularization exhibited in GFOGER hydrogels were insensitive to delivery of both low 
and high doses of exogenous VEGF as shown by the equivalent levels of vessel volume, 
spacing, and number (Fig. 5B-D). Whereas no differences were seen in these parameters, 
high doses of VEGF did increase the frequency of larger diameter vessels for GFOGER 
hydrogels compared to VEGF-free and low VEGF dose conditions (Fig. 5F). Taken 
together, the µCT vascular analysis shows that for growth-factor free conditions, RGD 
hydrogels result in poor vascularization; however, addition of VEGF to these hydrogels 
increases vascularization of these bone defects. In contrast, GFOGER hydrogels show 
elevated levels of vascularization regardless of delivery of exogenous VEGF. The 
observation that VEGF-free GFOGER hydrogels show significantly increased 
vascularization compared to VEGF-free RGD hydrogels and similar levels of 
vascularization compared to low dose VEGF-delivering RGD hydrogels emphasizes the 













Figure 5: Vascularization of bone defects. (A) Representative 3D reconstructions of 
vascular structures within the bone defect for different adhesive peptides and VEGF doses 
(scale bar = 200 µm). (B, C, D) Vascular volume, number and spacing in bone defect 
respectively. (E, F) Vascular diameter histogram indicating blood vessel size distribution. 






We also performed immunostaining for CD31 and endomucin, which are specific 
markers for endothelial cells within capillary networks [248] (Fig. 6). RGD hydrogels 
having low and high doses of VEGF exhibited increased levels of CD31 and endomucin 
staining compared to VEGF-free RGD hydrogels. The staining also showed the presence 
of larger diameter vessels in the low dose group compared to the high dose group and 
VEGF-free gels, in agreement with the µCT vascular analyses. GFOGER hydrogels 
displayed robust staining for CD31 and endomucin independent of the VEGF dose. The 
histological analysis is fully consistent with the µCT results showing VEGF dose-
dependent increases in endothelial markers for RGD hydrogels and no VEGF-dependence 
in GFOGER hydrogels, underscoring the importance of integrin-specificity in the 











Figure 6: Representative images of endomucin and CD31 staining in bone defect samples. 






3.4.5 Effects of integrin-specificity on vascsulogenic protein secretion by MSCs 
A major finding from the in vivo vascularization study is the enhancement in 
vascularization for defects treated with GFOGER-functionalized hydrogels compared to 
RGD-presenting gels. The network formation assay showed no differences in endothelial 
cell tubulogenesis between these two integrin-specific ligands (Fig. 4). Therefore, we 
investigated whether integrin binding specificity could influence the vasculogenic potential 
of non-endothelial cells such as mesenchymal stem cells (MSCs).  During bone repair, 
MSCs secrete paracrine factors that increase the recruitment and proliferation of 
endothelial cells to form functional neovessels [249, 250]. Due to the influx of MSCs and 
osteoprogenitors immediately after bone injury [251], we speculated that differential 
integrin binding could result in differences in secreted factors by MSCs. We thus 
investigated the effect of integrin-specificity on the secretion of angiogenic proteins from 
MSCs encapsulated within GFOGER or RGD-functionalized hydrogels. Integrin-specific 
hydrogels containing human MSCs were cultured in osteogenic media for 7 days after 
which the conditioned media was analyzed through ELISA for VEGF and FGF-2 levels. 
Conditioned media from GFOGER hydrogels showed a significantly elevated 
concentration of VEGF when compared to that of RGD hydrogels (Fig. 7A). The 
GFOGER-dependent upregulation in angiogenic factor secretion was specific to VEGF, as 
secretion of FGF-2 was below the limit of detection of the assay for both GFOGER and 
RGD hydrogels (Fig 7B). These results demonstrate that MSCs cultured within hydrogels 





MSCs cultured in RGD hydrogels. This finding provides an explanation for the 
enhancements in vascularization observed in bone defects treated with GFOGER-







Figure 7: hMSCs encapsulated within GFOGER-functionalized hydrogels exhibit 
enhanced secretion of VEGF compared to hMSCs encapsulated within RGD-
functionalized hydrogels. (A, B) Quantification of VEGF or FGF-2 in the supernatant of 
hMSCs encapsulated within integrin-specific hydrogels in osteogenic differentiation 






3.4.6 Effect of VEGF-delivering hydrogels on bone repair 
We next analyzed the effects of VEGF delivery within integrin-specific hydrogels on 
the repair of non-healing bone defects. Hydrogel conditions and surgical procedures were 
consistent with the vascularization study, and bone healing was evaluated by µCT at 4 and 
8 weeks post-surgery. Bone defects treated with VEGF-free GFOGER-modified hydrogels 
exhibited 3-4 fold higher bone volume compared to those treated with VEGF-free RGD-
modified hydrogels at 4 and 8 weeks post-surgery (Fig. 8B,D). For GFOGER hydrogels, 
VEGF had no significant effect on bone formation at 4 and 8 weeks post-surgery, consistent 
with the vascularization analyses. For RGD hydrogels, low doses of VEGF significantly 
increased bone volume at 4 weeks, whereas high doses of VEGF showed similar levels of 
bone volume compared to VEGF-free RGD hydrogels. However, by 8 weeks post-surgery, 
there were no differences among VEGF-containing and VEGF-free RGD hydrogels (Fig. 
8B, D). These results demonstrate that in VEGF-free conditions, GFOGER hydrogels 
exhibit significantly increased bone formation compared to RGD hydrogels. Additionally, 
although increases in vascularization are noted, especially within RGD hydrogels, delivery 
of exogenous VEGF does not enhance bone repair in this murine critical-size defect for 






Figure 8: Bone volume for bone defects treated with VEGF-containing hydrogels. (A, C) 
Representative 3D reconstructions of radial defect at 4 and 8 weeks respectively with 
differing ligand and VEGF doses (scale bar = 200 µm). (B, D) Quantification of bone 








Non-healing bone defects and fractures represent a serious clinical problem with over 
1 million surgical procedures necessitating bone grafts performed annually in the USA 
alone and costing over $5 billion [252]. While the creation of a functional vascular network 
is considered a crucial factor in successful regeneration of bone defects, it is still unclear 
whether delivery of vasculogenic factors such as VEGF enhances bone repair [117, 121, 
230, 253]. Additionally, while the role that integrins play in the progression of angiogenesis 
in tumors has been of particular interest recently [254], the ability of integrin binding to 
direct vascularization in the context of biomaterial-directed tissue repair has not been 
investigated. In this study, we examined whether incorporation of VEGF into synthetic 
hydrogels functionalized with either the α2β1 integrin-targeting GFOGER ligand or the 
RGD peptide that mainly binds to αvβ3 integrin modulates both the vascularization and 
bone regeneration of critical-size bone defects. 
 Controlled and sustained delivery of VEGF constitutes an important parameter in 
the design of the hydrogel. In the strategy described here, VEGF is covalently tethered to 
the hydrogel precursor thus allowing for high retention efficiency once cross-linked. The 
protease-sensitive nature of the cross-linked material provides for controlled release of 
VEGF based on cell-mediated invasion and degradation of the hydrogel. This system 
results in a positive feedback loop in vivo where VEGF initiates cell invasion which 





a growth-factor based release system is retaining the biological activity of the protein. For 
delivery vehicles based on the encapsulation of proteins within solid matrices such as 
microparticles, the bioactivity of the protein is likely reduced [255]. In the described 
system, VEGF remains in a hydrated state throughout gelation. Furthermore, the 
conjugation of the PEG macromer to free thiols within VEGF does not affect the protein’s 
biological activity as endothelial cells exhibited heightened 3D network formation when 
encapsulated within VEGF-tethered hydrogels compared to those in VEGF-free 
conditions.  
Whereas no differences were observed for in vitro endothelial network formation 
between integrin-specific hydrogels, significant differences were observed in the 
vascularization of bone defects in vivo for hydrogels presenting different adhesive peptides. 
For VEGF-free conditions, GFOGER-functionalized α2β1-targeting hydrogels exhibited 
significantly increased vascular volume and density compared to RGD-functionalized 
αvβ3-targeting hydrogels. This difference may be attributed to multiple factors. Activation 
of the α2β1 integrin has been reported to increase osteogenic activity resulting in increased 
pro-angiogenic signals as osteoblasts and osteoprogenitors secrete large quantities of 
VEGF to support the survival and proliferation of surrounding endothelial cells [256-258].  
This observation potentially explains the findings that VEGF-free GFOGER-
functionalized hydrogels produce higher bone regeneration in vivo compared to VEGF-
free RGD-functionalized hydrogels. Additionally, while the αvβ3 integrin has often been 





vascularization is context-dependent [259]. Depending on the environment, cell type, and 
which molecules the integrin interacts with, the αvβ3 integrin can play either a pro- or anti- 
angiogenic role [260-262].  
For hydrogels incorporating VEGF, RGD hydrogels exhibited increases in blood vessel 
volume, number and density within the bone defect area compared to VEGF-free controls. 
This result is consistent with the well-established cross-talk between the β3 integrin subunit 
and VEGFR2. Mutation of the cytoplasmic tail of the β3 integrin results in impaired 
interactions with VEGFR2 which leads to inefficient phosphorylation of the dimerized 
VEGFR2 complex [151]. Downstream activation of FAK and JNK signaling pathways 
from VEGFR2 activity is also dependent on the co-activation of the αvβ3 integrin [263]. 
The ability for RGD hydrogels to activate the αvβ3 integrin could thus cause heightened 
sensitivity to the presence of VEGF within the defect microenvironment. In contrast, the 
level of vascularization for GFOGER-functionalized hydrogels was independent of VEGF 
dose, with VEGF-free as well as low and high doses of VEGF exhibiting high levels of 
vascularization. Notably, when MSCs were encapsulated within GFOGER hydrogels in 
vitro, the cells exhibited increased secretion of VEGF compared to those encapsulated 
within RGD hydrogels. This finding provides an explanation as to why in vivo 
vascularization in GFOGER hydrogels was elevated and insensitive to exogenous VEGF 
as the interaction between the hydrogel and invading MSCs may provide abundant levels 
of endogenous VEGF. Overall, the finding that VEGF-free, GFOGER hydrogels show 





similar levels of vascularization compared to VEGF-containing RGD hydrogels is 
noteworthy. The ability for integrin-specificity alone to instruct and guide levels of 
vasculogenesis and regulate biological activity of vasculogenic proteins highlights the 
importance of exploiting integrin-specificity in regenerative medicine applications. With 
the expensive and often significant regulatory issues associated with growth factor 
therapies, the ability to engineer scaffolds to reduce or completely eliminate the need for 
growth factors through simple functionalization techniques can greatly enhance the clinical 
efficacy of future regenerative medicine constructs. 
In addition to differences in vascularization for the integrin-specific hydrogels, 
integrin specificity also played a role in the regeneration of bone within the critical-size 
defects. VEGF-free, GFOGER-functionalized hydrogels exhibited higher bone repair at 
both 4 and 8 weeks in comparison to VEGF-free RGD-presenting hydrogels. Addition of 
VEGF however had no effect on bone formation at 8 weeks indicating that exogenously 
delivered VEGF is not sufficient to repair critical-size bone defects in this model. This 
conclusion does not rule out an important role for VEGF in bone repair. On the contrary, 
endogenous VEGF is necessary for bone repair as treatment with VEGF blocking 
antibodies inhibits the healing of bone defects [117]. Furthermore, mice lacking the 
VEGF165 and VEGF188 isoforms show abnormal vascular patterning along with significant 
decreases in trabecular bone volume and bone growth [264]. However, in terms of 
delivering exogenous VEGF to regenerate bone defects, studies demonstrate conflicting 





after delivery of VEGF [120, 121, 230, 231, 265, 266]. The inconsistencies between these 
reports could be related to the in vivo model, scaffold, or delivery kinetics. Exploration into 
strategies utilizing VEGF in conjunction with other stimuli such as other growth factors 
(e.g., BMP-2), further scaffold engineering, cell therapy or gene therapy could enhance its 
effects. 
3.6 Conclusion 
While endogenous VEGF is known to be essential to osteogenesis, the ability of 
exogenously delivered VEGF to significantly repair bone defects remains ambiguous. In 
this study, we investigated whether integrin-specific biomaterials could constitute a crucial, 
yet, up to now, unexplored role in vascularization and osteogenesis in bone defects. VEGF-
free GFOGER-presenting hydrogels exhibited significantly increased vascularization and 
bone formation in a non-healing segmental bone defect compared to RGD-functionalized 
hydrogels. Furthermore, RGD-presenting hydrogels exhibited exogenous VEGF dose 
dependent increases in vascularization. Nevertheless, addition of VEGF to these hydrogels 
did not enhance bone repair in this bone defect model.  This study demonstrates interplay 





CHAPTER 4. AIM 2: IFN- FUNCTIONALIZED HYDROGELS 
FOR ENHANCED MSC-BASED IMMUNOMODULATION 
4.1 Abstract 
Human mesenchymal stem cells have recently garnered attention for their ability to 
treat a variety of chronic inflammatory diseases such as inflammatory bowel disorders due 
in part to their immunomodulatory properties. Treating hMSCs with IFN-γ prior to 
administration has been shown to augment these immunomodulatory properties. However, 
the ex vivo manipulation of these cells severely limits their clinical potential due to the 
prolonged handling and associated heightened cost and regulatory hurdles. In this study, 
we engineered a hydrogel with covalently tethered IFN-γ that can interact with 
encapsulated hMSCs to increase their immunomodulatory properties and thus avoid the 
need for ex vivo manipulation. Following verification of successful tethering of IFN-γ onto 
our scaffold, we found that hMSCs encapsulated within tethered IFN-γ hydrogels had 
significantly increased expression of indoleamine 2,3-dioxygenase (IDO) and programmed 
death ligand-1 (PD-L1) as well as increased expression of a variety of cytokines. Moreover, 
hMSCs within these IFN-γ bound hydrogels exhibited a potent ability to halt activated T-
cell proliferation and monocyte-derived dendritic cell differentiation compared to hMSCs 
that were pre-treated with IFN-γ and control hMSCs. Importantly, hMSCs encapsulated in 





colonic wounds in mice. Altogether, this novel methodology of licensing hMSCs with IFN-
γ can significantly increase both the efficacy and translatability of these cells into the clinic.   
4.2 Introduction 
Human mesenchymal stem cells (hMSCs) are a type of multipotent stromal cell that, 
in addition to having an ability to differentiate into a variety of cell types including bone, 
cartilage and fat, exhibit potent immunomodulatory capabilities [152, 267-269]. In vitro, 
co-culturing MSCs with activated T-cells or monocytes leads to reduced proliferation of 
T-cells and an inhibition of monocyte-derived dendritic cell differentiation, respectively 
[164, 186]. HMSCs have also been shown to have potent inhibitory effects on other 
immune cell types ranging from natural killer cells to B cells [168, 270]. The effects seen 
in vitro also extend to in vivo applications as hMSCs have been shown to have significant 
effects on ameliorating a range of autoimmune diseases in pre-clinical models of graft vs 
host disease (GvHD), experimental colitis and experimental autoimmune 
encephalomyelitis [8, 271-273]. With the observed success in pre-clinical models, hMSCs 
have been utilized in clinical trials for treating Crohn’s disease as well as steroid-refractory 
acute GvHD but with varying levels of success. In a phase II clinical study of refractory 
Crohn’s disease, although the overall disease score was significantly reduced with 
administration of hMSCs for group as a whole, the patient improvement was only noted in 
7 of 15 patients [214]. For GvHD, Le Blanc and colleagues found that out of 55 patients 





the other 25 had either a partial or no response to MSC therapy [207]. Overall, these studies 
as well as others point to the notion that while hMSC therapy aids in the amelioration of 
autoimmune diseases, but the effect is only seen in approximately half of patients, thus 
leaving vast room for improvement [208, 215]. 
 In order to enhance the efficacy of stem cell-therapy, it is necessary to understand 
the underlying mechanisms of hMSC-based immunomodulation. While the exact 
molecular mechanisms of how hMSCs generate such a potent response are still being 
elucidated, evidence points to the necessity for hMSCs to be activated with a pro-
inflammatory stimulus, notably interferon-gamma (IFN-γ), in order to elicit their 
immunomodulatory activities, a term known as ‘licensing’ [172, 274]. This has been 
confirmed by the observation that by either co-culturing hMSCs with IFN-γ deficient 
immune cells or using antibodies to neutralize IFN-γ, hMSCs lose the ability modulate 
immune cell phenotype [216, 275]. Once licensed with IFN-γ, hMSCs elicit their 
immunomodulatory effects by the IFN-γ-induced upregulation of various 
immunomodulatory factors including indoleamine 2,3-dixygenase (IDO), programmed 
death ligand-1 (PD-L1), prostaglandin E2 (PGE2), CCL8, CXCL9 and CXCL10 among 
many others [276, 277]. 
Importantly, the timing and duration of licensing are crucial and it has been shown 
that licensing hMSCs prior to co-culture or use in vivo enhances their immunomodulatory 





prior to co-culture with activated T-cells results in both inhibited T-cell proliferation and 
T-cell effector functions, while hMSCs that were not licensed prior to co-culture only 
inhibited T-cell proliferation [174]. Furthermore, licensing hMSCs prior to infusion into 
mice with GvHD results in enhanced hMSC-based suppression of the GvHD compared to 
that of un-licensed hMSCs [216]. Duijvestein and colleagues also showed that delivering 
pre-licensed hMSCs significantly reduced the severity of experimental colitis in a murine 
model compared to un-licensed hMSCs [279]. From a translatability standpoint however, 
pre-licensing hMSCs raises serious concerns due to the significant cost and logistics 
necessary for such processing. Ex vivo manipulation, for example, runs into countless 
issues such as creating an efficient manufacturing process which complies with GMP 
standards and regulation [280, 281]. Furthermore, the increased cost necessary with manual 
or even automated processing presents a key burden that has contributed to the bankruptcy 
of many companies offering cell therapy [282].  Generating a solution that bypasses the 
need for such processing would potentially enhance the translatability and efficacy of stem-
cell therapy.   
 Engineered biomaterials offer the potential for a solution to the need of ex vivo 
manipulation through scaffolds that can provide necessary cues to encapsulated cells. 
Through either covalent tethering or non-covalent affinity interactions, various groups 
have engineered scaffolds that bind proteins and other factors for either influencing 
encapsulated cells or interacting with the local microenvironment once implanted in vivo 





growth factor onto a poly(ethylene) glycol-based hydrogel significantly increases 
encapsulated endothelial cell tubulogenesis as well as induces increased vascularization in 
vivo compared to non-functionalized hydrogels [127, 131, 222]. There has been very little 
research done, however, in engineering a scaffold to license encapsulated hMSCs and 
enhance their immunomodulatory capabilities. Thus, the objective of this study was to 
engineer a scaffold exhibiting a covalently-bound form of IFN-γ for providing a persistent 
licensing cue for activation of hMSCs. We hypothesize that hMSCs encapsulated within 
this scaffold will elicit enhanced immunomodulation on immune cells in vitro as well as 
enhance the regeneration of colonic wounds in a mouse model. This data will provide much 
needed insight on whether biomaterials in conjunction with protein cues can act as an 
effective licensing agent and suitable for use in pre-clinical inflammatory models.  
4.3 Materials and Methods: 
4.3.1 Cell culture 
All human cell isolation and culture procedures were performed following IRB-
approved protocols. Human mesenchymal stem cells were acquired from the NIH Resource 
Center at Texas A&M University and grown in MEM-α containing 16% fetal bovine serum 
(FBS), 2 mM L-glutamine and 100 U/mL penicillin/streptomycin (ThermoFisher, MA). 
Human CD4+ T-cells were purified from frozen leukapheresis samples from Emory 
University through negative selection with a CD4 T-cell isolation kit according to the 





peripheral blood mononuclear cells (PBMCs). Briefly, peripheral blood was diluted 1:1 
with PBS containing 2% FBS after which the peripheral blood mononuclear cells (PBMCs) 
was separated via density gradient centrifugation (specific gravity: 1.077 g/mL, Stemcell 
Technologies, Canada). The isolated PBMCs were washed and subjected to monocyte 
purification using the EasySep human monocyte isolation kit (Stemcell Technologies, 
Canada) according to the manufacturer’s instructions. All cell culture was conducted at 37 
⁰C in a 5% CO2 atmosphere.   
4.3.2  PEG hydrogel synthesis and IFN-γ functionalization 
Four-arm maleimide-end functionalized PEG macromer (PEG-4MAL 20kDa MW, 
Laysan Bio, AL, >95% purity, >95% end-functionalization) was functionalized with IFN-
γ engineered to express a surface-exposed cysteine at amino acid position 103 (Boulder 
Biotechnology, CO) [286] for one hour at room temperature in phosphate buffered saline 
at pH=7.4. The macromer was further functionalized RGD peptide (GRGDSPC) 
(Genscript, NJ). The functionalized macromers were cross-linked using a mixture of the 
bi-cysteine peptide VPM (GCRDVPMSMRGGDRCG) (Genscript, NJ) and dithiothreitol 
(Sigma-Aldrich, MO). The PEG-4MAL hydrogels were synthesized to obtain a final 
concentration of 1.0 mM RGD peptide and a concentration of 25 µg/mL IFN-γ unless 
otherwise noted. The concentration of cross-linker used for the synthesis of each hydrogel 
was calculated by matching the number of cysteines in the cross-linking solution to the 





experiments, the cysteine-variant IFN-γ was substituted for the non-cysteine-containing 
human recombinant IFN-γ (Biolegend, CA). Cysteine-expressing IFN-γ functionalized 
into the PEG-4MAL hydrogel is termed ‘cys-IFN-γ hydrogels’ whereas non-cysteine-
expressing IFN-γ mixed into the PEG-4MAL hydrogel precursor is termed ‘IFN-γ 
hydrogels’. In experiments where cells were encapsulated in hydrogels, a pre-determined 
number of cells were mixed with the functionalized macromer followed by cross-linking. 
Hydrogels were allowed to gel at 37 ⁰C for 10 minutes before swelling in either PBS or 
complete cell culture media if cells were encapsulated in the hydrogel. Functionalization 
of the cysteine-expressing IFN-γ onto PEG-4MAL was determined through protein gel 
electrophoresis on an SDS-PAGE gel followed by protein visualization with Sypro Ruby 
according to manufacturer’s instructions (ThermoFisher, MA)  
4.3.3 IFN-γ release kinetics 
To assess IFN-γ release kinetics from hydrogels, hydrogels were synthesized with 
either cys-IFN-γ or IFN-γ. Hydrogels were incubated in PBS for 4 days with supernatant 
collected at specified time points, snap-frozen and stored at -80⁰C. At day 4, the PBS from 
all wells was removed and replaced with fresh PBS with a subset of wells having hydrogels 
having cys-IFN-γ, receiving PBS with 50 µg/mL collagenase (Worthington Biochemical, 
NJ). Supernatants were collected at specified time points for an additional 3 days, snap-
frozen and stored at -80⁰C. At the end of the experiment, samples were thawed and the 





4.3.4 Bioactivity of cys-IFN-γ 
HMSCs were plated onto 24-well tissue culture plastic plates at a density of 10,000 
cells/cm2. Four hours after seeding, various forms of IFN-γ were added to the cultures at a 
concentration of 50 ng/mL. After four days in culture, the conditioned media was collected 
and frozen at -80⁰C. HMSCs were trypsinized, fixed, permeabilized and subjected to flow 
cytometric analysis on a BD Accuri C6 flow cytometer for expression of IDO and PD-L1. 
Conditioned media was analyzed for secreted proteins using a custom Luminex kit (R&D 
Systems, MN).  
4.3.5 Cys-IFN-γ in hydrogel-encapsulated hMSC culture 
HMSCs were encapsulated in hydrogels containing cys-IFN-γ, IFN-γ or no IFN-γ 
as described above at a concentration of 5 x 106 cells/mL. After four days in culture, 
conditioned media was collected and frozen at -80⁰C. Hydrogels were then degraded by 
incubation in 1 mg/mL collagenase in PBS for 30 minutes at 37 ⁰C. Cells were collected 
and subjected to flow cytometric analysis for expression of IDO and PD-L1. Conditioned 
media was analyzed for various proteins using a custom Luminex kit (R&D Systems, MN). 
4.3.6 IDO activity / kynurenine assay 
Tryptophan is converted to kynurenine through IDO activity [287]. Kynurenine 
was quantified using a protocol previously described [288]. Briefly, 150 µL of conditioned 





µL of 30% trichloroacetic acid. This solution was then heated to 50 ⁰C for 10 minutes. 
Solutions were then vortexed and centrifuged at 10,000g for 5 minutes. 75 µL of 
supernatant samples were mixed with 75 µL of Ehrlich’s reagent and incubated for 10 
minutes. Absorbance was then read at 492 nm. 
4.3.7 T-cell proliferation assay 
HMSCs (1 x 106 cells/mL) were encapsulated in hydrogels (20 µL) with cys-IFN-
γ, IFN-γ, or no IFN-γ. For the pre-licensed group, hMSCs on tissue culture plastic were 
stimulated with IFN-γ for 48 hours prior to encapsulation in no IFN-γ hydrogels. To 
simulate in vivo applications in which a sink environment is present, cys-IFN-γ and IFN-γ 
hydrogels were washed two times over the course the first 24 hours following hydrogel 
synthesis. Following 48 hours of hMSC-hydrogel culture, CD4+ T-cells purified from 
PBMCs were resuspended in RPMI 1640 supplemented with 10% FBS, 2 mM L-
glutamine, 10 mM cell-culture grade HEPES and 100 U/mL penicillin/streptomycin. CD4+ 
T-cells (100,000) were added to each well in a 96 well plate and stimulated with 2 µL of 
Dynabeads (ThermoFisher, MA). HMSC-encapsulated hydrogels were then transferred to 
the wells containing the CD4+ T-cells and co-cultured for an additional 4 days. Eight hours 
prior to the end of culture, EdU was added to the media. At the end of 4 days, hydrogels 
were removed from the co-culture, T-cells were collected, fixed and permeabilized. T-cells 
were stained for DAPI and EdU that was incorporated into the T-cells upon proliferation 





instructions. Stained T-cells were imaged using a Nikon C2 confocal microscope and the 
proliferation of T-cells as quantified by taking the ratio of EdU+/total cells was performed 
using a custom ImageJ macro. In certain experiments, 1-methyl-L-tryptophan (1-MT) 
(Sigma-Aldrich, MO) was used to inhibit IDO activity. In these experiments, 1-MT was 
added to the media at the start of co-culture at a concentration of 1.0 mM 1-MT. The T-
cells were subjected to the same EdU staining protocol as described above.   
4.3.8 Monocyte-derived dendritic cell differentiation assay 
HMSCs were encapsulated in cys-IFN-γ, IFN-γ or no IFN-γ hydrogels (20 µL) at a 
concentration of 2.5 x 106 cells/mL. For the pre-licensed group, hMSCs on TCP were 
stimulated with IFN-γ for 48 hours prior to encapsulation in no IFN-γ hydrogels. To 
simulate in vivo applications in which a sink environment is present, cys-IFN-γ and IFN-γ 
hydrogels were washed two times over the course the first 24 hours following hydrogel 
synthesis. Hydrogels were cultured in this manner for 48 hours. Following 48 hours of 
hMSC-encapsulated hydrogel culture, purified human monocytes were isolated from 
peripheral blood and monocytes (500,000) were added into wells of a 24-well plate. 
Monocytes were cultured in RPMI 1640 supplemented with 10% FBS, 2 mM L-glutamine, 
100 U/mL penicillin/streptomycin, 50 ng/mL GM-CSF (Biolegend, CA) and 20 ng/mL IL-
4 (Biolgend, CA). HMSC-encapsulated hydrogels were then transferred to the wells 
containing monocytes and co-cultured for 5 days with media changes every 2-3 days. At 





to induce maturation of dendritic cells. Cells were cultured for an additional 48 hours after 
which the monocytes were gathered and subjected to flow cytometric analysis for CD1a, 
CD14, CD80 and CD86 on a BD Accuri C6 flow cytometer. In certain experiments, 1-
methyl-L-tryptophan (1-MT) (Sigma-Aldrich, MO) was utilized to inhibit IDO activity. In 
these experiments, 1-MT was added to the media at the start of co-culture at a concentration 
of 1.0 mM 1-MT. The differentiated monocytes were subjected to the same flow cytometric 
analysis as described above.  
4.3.9 Subcutaneous hydrogel injections 
All animal experiments were performed with the approval of the Georgia Tech Animal 
Care and Use Committee within the guidelines of the Guide for the Care and Use of 
Laboratory Animals. NOD SCID gamma (NSG) male mice (8-10 weeks old, Jackson 
Laboratories) were anesthetized under isoflurane and fur removed from the dorsal back. 
The skin was swabbed with chlorohexidine and alcohol. The entire dorsal back was divided 
into four separate quadrants. 50 µL hydrogel solutions or hMSCs in saline were injected 
via a 31g syringe needle into each of the four quadrants. Mice were monitored post-
injection for lethargy, weight loss, normal eating habits and signs of distress. After 3 days 
post-injection, mice were euthanized via CO2 inhalation. Hydrogels and the tissue 
surrounding the injection site were explanted via a 10 mm radius biopsy punch and 
immediately frozen at -80⁰C. To analyze cytokines, samples were mixed with tissue 





sodium deoxycholate) and protease inhibitors (ThermoFisher, MA). Total protein content 
and cytokine analysis was performed via a BCA assay and Luminex assay respectively 
according to manufacturer’s instructions. 
4.3.10 Colonic wound surgery and injections 
All animal experiments were performed with the approval of the University of 
Michigan Animal Care and Use Committee within the guidelines of the Guide for the Care 
and Use of Laboratory Animals and in accordance with the US Department of Agriculture 
(USDA) Animal and Plant Health Inspection Service (APHIS) regulations and the National 
Institutes of Health (NIH) Office of Laboratory Animal Welfare (OLAW) regulations 
governing the use of vertebrate animals. Colonic wounds were induced in a method similar 
to previously published protocols [289]. Briefly, male (8 weeks old) NOD-SCID IL2Rg-
null (NSG) mice (Jackson Laboratory) were anaesthetized by intraperitoneal injection of a 
ketamine (100 mg/kg)/xylazine (10mg/kg) solution. A high-resolution miniaturized 
colonoscope system equipped with biopsy forceps (Coloview Veterinary Endoscope, Karl 
Stortz) was used to biopsy-injure the colonic mucosa at 5 sites along the dorsal artery. 
Wound size averaged approximately 1 mm2. 50 µL hydrogel injections were performed 1 
day following wounding with the aid of a custom-made device comprising a 29-gauge 
needle connected to a small tube. Endoscopic procedures were viewed with high-resolution 
(1,024 x 768 pixels) live video on a flat-panel color monitor. Each wound region was 





area was calculated by a blinded observer using ImageJ. Results for one mouse were 
averaged through quantification of the five colonic wounds/injections per mouse.  
4.3.11 Statistics 
Unless otherwise noted, error bars on graphs represent SEM. Comparisons among 
multiple groups was performed by one-way analysis of variance (ANOVA) with post-hoc 
Tukey tests if data did not have significant differences in standard deviation. Data with 
significant differences in standard deviation were subject to log transformation after which 
post-hoc Tukey test performed. All statistics were performed in Graphpad Prism version 
6. A p value of <0.05 was considered significant. 
 
4.4 Results 
4.4.1 IFN-γ functionalization onto PEG-MAL and release kinetics 
 
We engineered hydrogels based on a maleimide-functionalized 4-arm PEG (PEG-
4MAL) macromer which allows for facile covalent tethering of proteins exhibiting a 
surface-accessible cysteine. Further reaction of the PEG-4MAL with a protease-degradable 
bicysteine peptide results in an insoluble and cross-linked PEG-based hydrogel sensitive 





acid sequence and thus no ability to conjugate onto a PEG-MAL macromer through a 
maleimide-cysteine reaction without addition of other linking reagents. To circumvent this, 
we utilized an IFN-γ variant that is genetically engineered to express a surface-available 
cysteine residue at amino acid position 103 [286]. To verify that this variant could be 
functionalized onto a PEG macromer, protein gel electrophoresis was performed (Fig. 9B). 
The cysteine-expressing IFN-γ (cys-IFN-γ) that was not functionalized with PEG-MAL 
and instead mixed with PBS exhibited a distinct single band at approximately 17 kDa as 
expected. When the IFN- was reacted with PEG-MAL macromer (20 kDa), no band is 
seen at the 17 kDa and instead the band is shifted to greater than 30 kDa indicating 
successful conjugation. To further verify the tethered nature of this cys-IFN-γ, we also 
performed a release assay in which either cys-IFN-γ or IFN-γ was incorporated into 
hydrogels (Fig. 9C). Native IFN-γ does not have a cysteine and thus cannot be covalently 
conjugated to PEG-4MAL and therefore not tethered into the hydrogel. Upon synthesis, 
hydrogels were placed in PBS and samples removed at specified time-points for analysis 
by ELISA. Non-tethered IFN-γ exhibited a significant ~62% burst release after only 2 
hours followed by complete release by 18 hours. In contrast, cys-IFN-γ that was 
functionalized onto the PEG-MAL prior to gelation released ~10% of total incorporated 
IFN-γ after 2 hours and after 4 days, still retained approximately 65% of total incorporated 
protein. To show that this retention is dependent on hydrogel degradation as the IFN-γ is 
tethered to the polymeric backbone, at 4 days, a subset of cys-IFN-γ hydrogels were 





degradation of the hydrogel through the degradable cross-linkers over the course of the 
following three days and resulted in complete cys-IFN-γ release. Together, the protein gel 
electrophoresis and release results verify that the cys-IFN-γ can be chemically conjugated 







Figure 9: Tethering of IFN-γ onto PEG-4MAL hydrogels and degradation-dependent 
release. (A) Schematic representing cytokine functionalization with adhesive ligand, 
hMSC and protease-degradable cross-linker incorporation. (B) Protein gel electrophoresis 
with functionalized IFN-γ onto PEG-4MAL. Lane 1) protein ladder, lane 2) Cys-IFN-γ 





by ELISA. All groups were incubated in PBS until 4 days at which point collagenase (50 
µg/mL) was added to the respective group. N=5. Error bars ± SEM. 
4.4.2 Biological activity of PEGylated IFN-γ 
To assess whether biological activity is affected by the chemical conjugation of the 
cys-IFN-γ onto PEG-4MAL, hMSCs were plated on tissue-culture plastic wells and 
incubated in cell culture supplemented with either cys-IFN-γ + PEG-4MAL, the cys-IFN-
γ without PEG-4MAL, native IFN-γ, PEG-4MAL without IFN-γ or no additives. HMSCs 
exposed to native IFN-γ exhibit upregulated IDO and PD-L1 activity as well as secrete 
differing levels of cytokines [174, 175, 290]. To determine whether the biological activity 
of both the cys-IFN-γ as well as its PEG-4MAL conjugated state, we performed flow 
cytometric analysis for IDO and PD-L1 activity as well as assessed certain cytokine 
concentrations through a custom Luminex kit. hMSCs incubated with cys-IFN-γ + PEG-
4MAL, cys-IFN-γ without PEG-MAL, or native IFN-γ all showed significantly increased 
levels of IDO and PD-L1 activity as assessed by median fluorescence intensity (MFI) 
compared to hMSCs incubated with PEG-4MAL or with cell culture media alone (Fig. 
10A,B). Importantly, there were no significant differences in the MFI of IDO or PD-L1 
among hMSCs exposed to either the cys-IFN-γ + PEG-4MAL, the cys-IFN-γ or native 
IFN-γ, indicating that the cys-IFN-γ has similar biological activity to the native protein and 
that further conjugation also does not hinder its activity. Furthermore, upon analysis of the 





significantly different among the tested groups. Specifically, concentrations of IL-6, 
CXCL10, CCL2, CCL8, and M-CSF were all significantly increased while VEGF was 
significantly decreased in all forms of IFN-γ treated conditions compared to groups not 
treated with IFN-γ (Fig. 10C-H). No significant differences were noted between cys-IFN-
γ + PEG-4MAL, cys-IFN-γ or native IFN-γ for IL-6. cys-IFN-γ + PEG-4MAL did show 
significant decreases in CXCL10, CCL2, VEGF, CCL8 and M-CSF compared to cys-IFN-
γ without PEG-4MAL and native IFN-γ, but these levels were higher than levels for 








Figure 10: hMSCs on tissue culture plastic exhibit significant changes in marker expression 
and secretome when incubated with IFN-γ in all forms compared to hMSCs without IFN-





PEG-4MAL or with no treatment. Following 4 days, hMSCs were stained for (A) IDO and 
(B) PD-L1 and subjected to flow cytometry. Conditioned media was analyzed for 
concentrations of various proteins including (C) IL-6, (D) CXCL10, (E) CCL2, (F) VEGF, 
(G) CCL8 and (H) M-CSF. Dotted lines signify limit of detection for specific protein. N=6. 





4.4.3 HMSC phenotype in hydrogels with tethered IFN-γ 
Following verification of the biological activity of PEG-4MAL-conjugated IFN-γ 
on hMSCs seeded on tissue-culture plastic, we examined whether cys-IFN-γ hydrogels 
modulated the phenotype of hydrogel encapsulated-hMSCs. HMSCs were encapsulated in 
hydrogels having doses of cys-IFN-γ ranging from 0-25 µg/mL. Following 4 days in 
culture, MSCs were subjected to flow cytometric analysis for IDO and PD-L1 (Fig. 11A). 
The expression of PD-L1 decreased as concentration increased from 0 to 5 µg/mL but then 
increased from 5 to 25 µg/mL. Notably, IDO expression increased significantly with 
increasing cys-IFN-γ concentration in a dose-dependent fashion. We also verified that 
increased IDO expression as seen determined by flow cytometric analysis correlated with 
IDO activity by measuring the concentration of kynurenine, the product of tryptophan after 
its catalysis by IDO (Fig. 11B).  
After this dose-dependent study, we sought to understand how the polymer density 
of the hydrogel influences the expression of IDO and PD-L1. HMSC-encapsulated 
hydrogels of differing polymer densities ranging from 4% to 10% were synthesized with a 
constant 25 µg/mL concentration of cys-IFN-γ. Following 4 days in culture, MSCs were 
subjected to flow cytometric analysis for expression of IDO and PD-L1 (Fig. 12A, B). 
Whereas no differences were noted for PD-L1 expression, MSCs within 10% PEG weight 
hydrogels exhibited significantly lower levels of expression of IDO compared to those in 





properties study, we chose to focus on 6% hydrogels with a 25 µg/mL IFN-γ dose in 








Figure 11: IDO and PD-L1 expression are functions of cys-IFN-γ dose. (A) HMSCs were 
encapsulated within 20 µL 6% PEG weight hydrogels having differing doses of cys-IFN-γ 
and placed in 1 mL of media. After 4 days in culture, hMSCs were stained for IDO and 
PD-L1 and subject to flow cytometric analysis. N=3-5. Error bars ± SEM (B) Conditioned 
media at select doses was tested for kynurenine concentration to verify correlation of IDO 
expression with IDO activity. Dotted line signifies concentration of kynurenine in hMSC 







Figure 12: IDO is a function of PEG weight percent. HMSCs were encapsulated within 20 
µL hydrogels of varying PEG weight percentages and 500 ng cys-IFN-γ. After 4 days in 
culture, hMSCs were stained for IDO and PD-L1 and subject to flow cytometric analysis. 






4.4.4 Transient licensing of IFN-γ hydrogels compared to cys-IFN-γ hydrogels 
While cys-IFN-γ exhibits the ability to license hMSCs within our hydrogel 
construct, we further explored whether tethering significantly increased licensing duration 
compared to a non-tethered form of IFN-γ. HMSCs were encapsulated in hydrogels with 
either cys-IFN-γ, IFN-γ or no IFN-γ. Following encapsulation, hydrogels were washed 
throughout the first 24 hours to simulate sink conditions present in vivo. Hydrogels were 
then cultured for an additional 3 days after which the hydrogels were degraded, conditioned 
media collected for cytokine analysis and hMSCs stained for IDO and PD-L1 followed by 
flow cytometric analysis (Fig. 13A,B). HMSCs encapsulated in IFN-γ hydrogels exhibited 
significantly increased IDO and PD-L1 expression compared to control hMSCs. 
Importantly however, hMSCs encapsulated in cys-IFN-γ hydrogels showed significantly 
increased IDO and PD-L1 expression compared to hMSCs encapsulated in IFN-γ 
hydrogels as well as control hMSCs. Additionally, analysis of conditioned media showed 
that hMSCs encapsulated in cys-IFN-γ hydrogels secreted increased levels of CXCL10, 
CCL2, CCL8, M-CSF and CXCL9 compared to hMSCs encapsulated in either IFN-γ 






Figure 13: IDO and PD-L1 expression of hMSCs in hydrogels with cys-IFN-γ and IFN-γ. 
Following 4 days of culture, hMSCs in hydrogels with either cys-IFN-γ, IFN-γ or no IFN-
γ were stained for (A) IDO and (B) PD-L1 and subjected to flow cytometric analysis. N=6 
separate hydrogel with 5000 hMSCs analyzed per hydrogel. Error bars ± SEM. One-way 






Figure 14: Cytokine analysis of conditioned media. Conditioned media of hMSCs 





IL-6, (B) CXCL8, (C) CCL7, (D) CXCL10, (E) CCL2, (F) VEGF, (G) CCL8, (H) 
CXCL16, (I) M-CSF and (J) CXCL9. N=6. Error bars ± SEM. One-way ANOVA. * 






4.4.5 HMSCs encapsulated in cys-IFN-γ hydrogels significantly inhibit T-cell 
proliferation via an IDO-dependent mechanism 
HMSCs have been noted to elicit immunomodulatory properties on a variety of 
immune cell types. Notably, hMSCs significantly reduce the proliferation of activated T-
cells when co-cultured together [164]. Given the significant effect that cys-IFN-γ has on 
encapsulated hMSCs compared to hMSCs encapsulated in IFN-γ hydrogels, we next 
assessed whether cys-IFN-γ hydrogels could augment the inhibitory effect of hMSCs on 
T-cell proliferation (Fig 15). HMSCs were encapsulated in hydrogels with either cys-IFN-
γ, IFN-γ, or no IFN-γ. Additionally, we wanted to further test the functional ability for 
hMSCs encapsulated in cys-IFN-γ hydrogels to hMSCs licensed with IFN-γ prior to 
utilization in therapy as is routinely done. Thus, in a separate group, hMSCs were 
encapsulated in hydrogels without IFN-γ and incubated in media having 500 ng/mL native 
IFN-γ. HMSCs in cys-IFN-γ and IFN-γ hydrogels were washed twice within 24 hrs 
following encapsulation to simulate a sink effect in vivo. These hydrogels were then 
incubated with activated CD4+ T-cells and co-cultured for 4 days after which the T-cells 
were stained for EdU and CD3 to examine proliferation and verify their T-cell phenotype, 
respectively (Fig. 15). Activated T-cells cultured solely with Dynabeads (to activate T-
cells) showed a similar high degree of proliferation compared to activated T-cells cultured 
with a cys-IFN-γ hydrogel without hMSCs indicating that the presence of the cys-IFN-γ 
hydrogel by itself has no effect on T-cell proliferation (Fig. 16). Furthermore, these two 





having IFN-γ. Importantly however, T-cells incubated with hMSCs in cys-IFN-γ hydrogels 
exhibited significantly lower levels of proliferation compared to T-cells cultured with 
hMSCs in IFN-γ hydrogels, indicating augmented immunomodulatory properties for 
tethered IFN-γ over non-tethered forms. There were no differences in T-cell proliferation 
for T-cells incubated with hMSCs in cys-IFN-γ hydrogels or hydrogels with pre-licensed 
hMSCs. 
We further assessed the mechanism behind this inhibitory effect. Thus, hMSCs were 
encapsulated in cys-IFN-γ hydrogels and co-cultured with T-cells (Fig. 17A). An IDO 
inhibitor, 1-methyl-tryptophan (1-MT), was either added or excluded from the media. After 
4 days, T-cells that were incubated with hMSCs encapsulated in cys-IFN-γ hydrogels 
without 1-MT exhibited significantly reduced proliferation compared to T-cells cultured in 
the same conditions with 1-MT (Fig. 17B). Importantly, T-cells cultured with 1-MT either 
with or without hMSCs showed no difference in their proliferation denoting that the 
addition of 1-MT completely inhibited the anti-proliferative effect of licensed hMSCs in 
the co-culture. This complete abrogation of anti-proliferative effect indicates that IDO is a 











Figure 15: Representative images of fluorescence microscopy images of proliferating T-







Figure 16: Quantification of proliferating T-cells. HMSCs encapsulated within cys-IFN-γ 
hydrogels significantly reduce activated CD4+ T-cell proliferation. Untreated or pre-
licensed hMSCs were encapsulated within cys-IFN-γ, IFN-γ or no IFN-γ hydrogels and co-
cultured with activated CD4+ T-cells for 4 days. T-cell proliferation was assessed via EdU 
incorporation. Graph shows samples from two independent experiments. N= 5-8 separate 
wells with quantification of >100 T-cells per well. Error bars ± SEM. One-way ANOVA 




















































































Figure 17: T-cell proliferation with IDO inhibitor. (A) Representative images of 
fluorescence microscopy images of proliferating T-cells with or without IDO inhibitor. 
Scale bars = 100 µm. (B) Quantification of proliferating T-cells. N= 6-7 separate wells 
with quantification of > 100 T-cells per well. Error bars ± SEM. All quantification of 








4.4.6 HMSCs encapsulated in cys-IFN-γ hydrogels significantly inhibit monocyte-
derived dendritic cell differentiation via a primarily IDO-dependent method 
In addition to inhibiting T-cell proliferation, hMSCs have been noted to inhibit the 
differentiation of monocytes into dendritic cells in vitro [186]. We thus assessed whether 
cys-IFN-γ hydrogels could augment the inhibition of dendritic cell differentiation (Fig. 
18A). Untreated or pre-licensed hMSCs were encapsulated within cys-IFN-γ, IFN-γ, or no 
IFN-γ hydrogels and co-cultured with peripheral blood purified CD14+ monocytes. These 
cells were co-cultured in dendritic cell differentiation conditions for 5 days. Mature 
dendritic cell differentiation was performed by addition of 100 ng/mL LPS for an additional 
2 days. Following complete differentiation, monocytes were stained for the monocyte 
marker CD14, the dendritic cell marker CD1a and maturation markers CD80 and CD86. 
Monocytes cultured in the absence of hMSCs exhibited significantly greater dendritic cell 
differentiation compared to monocytes co-cultured with hMSCs as quantified by the 
percentage of CD1a+/CD14- cells (Fig. 18A). Monocytes cultured with hydrogels having 
untreated hMSCs, pre-licensed hMSCs or hMSCs encapsulated in IFN-γ hydrogels showed 
no differences in their dendritic cell differentiation. Importantly however, monocytes 
cultured with hMSCs encapsulated in cys-IFN-γ hydrogels showed a significant reduction 
in their dendritic cell differentiation compared to monocytes cultured with all other hMSC 
conditions and IFN-γ. Furthermore, monocytes cultured with hMSCs encapsulated in cys-
IFN-γ hydrogels exhibited significantly greater expression of maturation markers CD80 





These results show that hMSCs in cys-IFN-γ hydrogels exhibit significantly upregulated 
ability to inhibit monocyte-derived dendritic cell differentiation compared to either hMSCs 
not exposed to IFN-γ or hMSCs in IFN-γ hydrogels. 
 We next investigated the mechanism of action for this effect and conducted an 
experiment where monocytes were co-cultured with either hMSCs in cys-IFN-γ hydrogels 
or alone with the addition of either an IDO inhibitor (1-MT), a PGE2 inhibitor (NS-398), 
or both. Following 7 days in dendritic cell differentiation conditions, the monocytes were 
collected, stained for CD1a and CD14 and subjected to flow cytometric analysis (Fig. 19). 
Without the addition of IDO or PGE2 inhibitor, monocytes co-cultured with hMSCs in cys-
IFN-γ hydrogels exhibited less dendritic cell differentiation compared to those without 
hMSCs. Monocytes co-cultured in the hMSC condition and cultured with the IDO or PGE2 
inhibitor exhibited more dendritic cell differentiation compared to vehicle only controls. 
Monocytes with the IDO inhibitor exhibited more dendritic cell differentiation than those 
with the PGE2 inhibitor indicating IDO to be the dominant mechanism halting dendritic 







Figure 18: hMSCs in cys-IFN-γ hydrogels inhibit dendritic cell differentiation. (A) 
Percentage of dendritic cells in monocyte culture after 7 days differentiation as defined by 
CD1a+ / CD14- by means of FMO controls. Median fluorescence intensity for markers (B) 
CD80 and (C) CD86. N=3-4 separate wells with 20,000 cells analyzed per well. Error bars 




119   
Figure 19: hMSC-based inhibition of monocyte differentiation is dictated primarily through 
IDO: (A) Isolation of monocytes from peripheral blood at day 0 resulted in 86.5% of cells 
displaying the CD14+ / CD1a- monocyte phenotype. After 7 days in dendritic cell 
differentiation conditions either (B-E) with or (F-I) without co-culturing with hMSCs 
encapsulated within IFN-γ tethered hydrogels and with or without IDO or PGE2 inhibitors 1-





4.4.7 HMSCs in cys-IFN-γ hydrogels exhibit differential cytokine expression in a murine 
subcutaneous environment compared to pre-licensed hMSCs 
Because we observed enhanced hMSC-based immunomodulation on cells from 
both myeloid and lymphoid lineages when hMSCs were encapsulated in cys-IFN-γ 
hydrogels compared to other forms of IFN-γ activation, we explored whether cys-IFN-γ 
hydrogels could augment hMSC immunomodulation in vivo. For this experiment, we 
utilized a murine subcutaneous model in which human cytokine analysis was performed 3 
days after hMSC-encapsulated hydrogels were injected into immunocompromised mice. 
HMSCs were encapsulated within cys-IFN-γ hydrogels or within hydrogels without IFN-
γ. We also encapsulated pre-licensed hMSCs which were incubated in 500 ng/mL IFN-γ 
for 48 hours prior to subcutaneous injection. These groups were injected in the 
subcutaneous space of the dorsum of mice. After 3 days post-injection, tissue explants were 
analyzed for a panel of human cytokines via a Luminex assay. Two-way hierarchical 
clustering of the 14 cytokines assessed showed distinct groupings among experimental 
conditions (Fig. 20). Furthermore, by performing canonical correlation analysis, distinct 
groupings are seen with larger separation between hMSCs in cys-IFN-γ hydrogels and 
other hMSC groups compared to pre-licensed hMSCs and hMSCs not treated with IFN-γ 
(Fig. 21). Individual cytokine analysis also revealed significant differences among tested 
groups (Fig. 22). In particular, it is interesting to note that for certain specific cytokines 
including IL-6 and VEGFA, the trends opposed were opposite of that measured in vitro. 





with differing cell types present in vivo compared to our in vitro system. That said however, 
it is worthy to note that many other cytokines that have been implicated in hMSC-based 
modulation of immune cell reaction such as M-CSF and MCP-1 follow similar trends seen 







Figure 20: Two-way hierarchical clustering analysis 
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Figure 22: Individual cytokine analysis from tissue extraction. N=7. Error bars ± SEM 






4.4.8 HMSCs in cys-IFN-γ hydrogels accelerate healing of colonic wounds  
Following our findings that hMSCs within cys-IFN-γ hydrogels show a different 
cytokine profile compared to either pre-licensed or untreated hMSCs within a subcutaneous 
model, we examined the use of hMSCs encapsulated within cys-IFN-γ hydrogels within a 
more functional model. The use of hMSCs toward treating inflammatory diseases in 
clinical trials has rapidly grown in recent years with Crohn’s and other inflammatory bowel 
diseases consisting a large portion of the conditions being treated [291]. In addition, 
previous literature suggests that licensing hMSCs with IFN-γ can significantly augment the 
regenerative effects of cell therapy in pre-clinical colitis models [221]. We thus tested 
whether hMSCs encapsulated within cys-IFN-γ hydrogels could significantly enhance 
regeneration of intestinal mucosal wounds. A preliminary pilot experiment demonstrated 
that hMSCs within cys-IFN-γ hydrogels accelerated the regeneration of colonic wounds 
compared to either controls where no treatment was injected or to wounds where cys-IFN-
γ hydrogels without hMSCs were injected (Appendix C). This pilot experiment 
demonstrates that colonic wounds in control animals without hMSCs do not heal as well 
as when hMSCs are delivered. This allows for future experiments to drill deeper on the 
question of whether hMSCs in cys-IFN-γ hydrogels outperform non-licensed or pre-
licensed hMSCs since the control group of no cells is already proved to be ineffectual.   
We thus conducted a larger scaled experiment where we focused on the issue of 





IFN-γ hydrogels or no IFN-γ hydrogels and injected at the site of mechanically induced 
mucosal wounds in the distal colon of mice. Additionally, we incorporated a group where 
hMSCs in saline were injected at the wound site. We also had a group, termed the control 
group, where un-cross-linked hydrogel components in saline were injected at the wound 
site. Five days post-injury, wound closure was assessed via a murine colonoscope and 
quantified. No differences in wound closure were noted between control mice and mice 
injected with hMSCs either in no IFN-γ hydrogels or in saline alone. However, hMSCs that 
were encapsulated within cys-IFN-γ hydrogels exhibited significantly higher levels of 







Figure 23: Regeneration of colonic wounds. (A) Representative images of colonic wounds 
at day 1 and day 5 after implantation. (B) Quantification of colonic wound closure at day 








With the impetus for cell therapies to be translated into the clinic, human 
mesenchymal stem cells have become a widely researched cell type with utilization in 
nearly 500 clinical trials [1]. While these cells were initially touted for their differentiation 
potential, recent evidence including their potential for treating inflammatory diseases such 
as graft vs host disease and Crohn’s disease point to their effects being due principally to 
their immunomodulatory properties [292, 293].  Nonetheless, the success of these clinical 
trials in treating inflammatory diseases is mixed with approximately half of all patients 
who were administrated hMSCs showing little to no improvement [207, 208, 214, 215]. 
This points to a need for increasing the efficacy of stem cell based therapy and specifically, 
increasing the immunomodulatory properties of hMSCs. Licensing hMSCs with IFN-γ has 
been noted to increase their immunomodulatory properties within both in vitro and in vivo 
systems [294]. However, the need for ex vivo manipulation of hMSCs with IFN-γ raises 
considerable concerns including the presence of increased costs, clearing regulatory 
hurdles and establishing rigorous and reliable cell handling practices that all negatively 
affect clinical translation [280]. Engineering a biomaterial that can license hMSCs without 
the need for ex vivo manipulation can significantly enhance the translation of stem cell 
therapy.  
In this study, we engineered a novel methodology for licensing hMSCs by 





To assess the functionality and efficacy of our platform, we tested two general concepts: 
1) whether the scaffold modification elicited a response onto scaffold-encapsulated hMSCs 
and 2) whether the effect imparted onto the hMSCs generated a secondary effect onto other 
cell types, specifically immune cells. For the former concept, hMSCs encapsulated within 
the modified hydrogel exhibited similar or increased expression of both cell-licensing 
markers IDO and PD-L1 compared to hMSCs that were pre-licensed with IFN-γ. For the 
latter concept, hMSCs encapsulated within modified hydrogels showed a potent ability to 
hinder both activated T-cell proliferation and monocyte-derived dendritic cell 
differentiation. Importantly, the monocyte hindrance imparted by hMSCs encapsulated 
within IFN-γ-modified hydrogels was greater than that of encapsulated hMSCs that were 
licensed with unbound IFN-γ prior to co-culture. This increased effect for the bound form 
could potentially be due to the increased duration of licensing as the bound IFN-γ form is 
present throughout the co-culture period while the unbound IFN-γ is removed prior to co-
culture as a simulation for how this treatment would be translated into the clinic. In addition 
to the increased duration, the bound form of IFN-γ presumably results in higher 
microenvironmental concentrations of IFN-γ surrounding the encapsulated hMSCs 
compared to the unbound form. This notion elicits the possibility for future studies 
investigating whether lower doses of cys-IFN-γ could be utilized thus furthering the 
applicability of clinical use.  
In addition to the in vitro results, the cytokine data gathered from the subcutaneous 





IFN-γ imparts a more significant effect than pre-licensed hMSCs. Through canonical 
correlation analysis of the cytokine data, it was observed that pre-licensed hMSCs 
exhibited a more similar cytokine signature to un-treated hMSCs than hMSCs within cys-
IFN-γ hydrogels. On an individual cytokine basis, hMSCs within cys-IFN-γ hydrogels 
showed significantly higher levels of the cytokine macrophage colony stimulating factor 
(M-CSF), which is known to skew monocytes toward an anti-inflammatory phenotype. 
Furthermore, within a functional model, hMSCs encapsulated in cys-IFN-γ hydrogels 
exhibited significantly higher levels of wound closure compared to controls as well as 
untreated hMSCs. This finding supports the notion that the effects imparted by this 
methodology of licensing hMSCs elicits a functional response in vivo. It remains unclear 
however the mechanisms behind the increased regeneration. Further studies are needed to 
understand how such licensing affects the cellular and molecular cascades within the 
affected area in order to further increase the efficacy of the therapy. While the levels of 
healing in the hMSC + cys-IFN-γ hydrogel group can be described as relatively modest 
compared to that of control groups, it is important to recognize that model carries some 
limitations. For one, the colonic wounds in control mice which received only saline 
injections exhibited approximately 47% wound closure by day 5. This indicates that even 
with no treatment, the wound heals by itself. Future experiments utilizing a more rigorous 







While hMSCs have been recently used for treating inflammatory diseases in clinic 
trials, their scale use is limited by issues with efficacy and ex vivo manipulation. In this 
study, we engineered a novel way to license hMSCs by covalently tethering IFN-γ within 
hMSC-encapsulated hydrogels. HMSCs within bound IFN-γ hydrogels exhibited 
significantly increased IDO activity compared to un-treated hMSCs as well elicited either 
equal or greater ability to hinder immune cell proliferation and differentiation compared to 
pre-licensed hMSCs. Furthermore, in a functional colonic wound model, hMSCs within 
tethered IFN-γ hydrogels exhibited significantly enhanced healing compared to untreated 
hMSCs. This study demonstrates the ability for covalently bound IFN-γ to enhance the 
immunomodulatory properties of hMSCs and enhances the clinical translatability of 






CHAPTER 5. FUTURE CONSIDERATIONS 
5.1 Vascularization and bone healing with human mesenchymal stem cells 
We have observed that integrin-specific hydrogels significantly impact the level of 
vascularization within a bone defect depending on the specific ligand the hydrogel is 
functionalized with (Chapter 3). Preliminary experiments in which integrin-specific and 
VEGF-functionalized hydrogels were encapsulated with hMSCs and delivered within the 
bone defect however showed no effect from either the integrin-specificity or the presence 
of VEGF on stem cell number in the defect as assessed via bioluminescence tracking 
(Appendix A). Future work to resolve this issue can revolve around ascertaining the cause 
of stem cell death and engineering the material to enhance short-term survival of hMSCs. 
The rationale for implanting hydrogels functionalized with VEGF was to improve the 
vascularization of the surrounding tissue, thereby increasing oxygen and nutrient 
availability to enhance implanted cell survival. However, the model used consists of a 
defect where the total diameter of the wounded bone is < 1 mm. This raises the possibility 
that the wound itself may not be under hypoxic stress. Future work may include inducing 
a wound followed by observation of hypoxic conditions through commercially available 
products such as hydroxyprobe. If hypoxic conditions exist, the presence of VEGF may 





implantation. Thus, work in which VEGF functionalization is combined with approaches 
aimed at enhancing cell survival in the short-term such as an oxygen-generating material 
within the hydrogel construct could increase the efficacy of the cell-based therapy.  
Preliminary experiments also showed that neither integrin-specificity nor VEGF 
functionalization onto hMSC-laden hydrogels had effects on vascularization or bone 
regeneration within the bone defect model (Appendix A). One potential reason for this 
dichotomy between the results with and without cells is the difference of immune-based 
parameters between experiments incorporating hMSCs and those without. Experiments 
without hMSCs were performed in C57 mice which have fully functioning immune 
systems while experiments with hMSCs were performed in immunodeficient mice. 
Mounting evidence points to the importance of the immune system in the successful 
resolution of bone defects [295]. The effect integrin-specificity has within a bone defect 
may be in part due to immune cell interactions which would be absent within 
immunodeficient mice. Utilizing human mesenchymal stem cells within humanized mice, 
which exhibit a fully functional immune system, will be required to definitively ascertain 
the role of the immune system on our hydrogel construct and increase the relevance of the 
findings.  
5.2 Immunomodulation by MSCs 
In Aim 2 of this thesis, we engineered a PEG hydrogel in which IFN-γ was covalently 





and was able to interact with hMSCs to enhance their immunomodulatory properties both 
in vitro and in vivo. There are multiple directions that this research can continue forth to. 
Maintaining with the inflammatory bowel disease model, further studies can be performed 
understanding how our platform compares to the current gold standard consisting of pre-
licensing the cells with IFN-γ prior to implantation. While our platform can theoretically 
avoid the use of ex vivo manipulation thus enhancing its clinical translation, it would be 
important to understand how a persistent IFN-γ signal in vivo compares to an IFN-γ 
stimulus prior to treatment in a functional manner. Additionally, one area that can be 
explored is that of the mechanism of action underlying the increased regeneration noted in 
the colonic wound model. In vitro results noted that both T-cells and monocytes are 
affected by licensed hMSCs; however, the inflammatory and regenerative signals 
following injury involve a complex cascade of events which make it difficult to properly 
and precisely carry interpretation from in vitro studies into in vivo scenarios. Flow 
cytometric-based phenotyping of the wound at different time-points following colonic 
injury and hydrogel injection would provide insight into the cellular environment. This 
analysis could also provide insight into the polarization of the various cells to indicate 
whether a shift into an anti-inflammatory state occurs. Once the mechanism of action is 
understood, it is also plausible to move into more clinically relevant models of 
inflammatory bowel disease rather than that of a mechanically induced colonic injury. 
There are a variety of knock-out murine models where colitis spontaneously occurs 





emulate colitis. While knockouts can result in colitis, the systemic effects of knockout can 
limit the interpretation of results and so a transgenic model where colitis can be selectively 
induced provide more relevant models. A soluble B7.2 transgenic model results in mice 
that are genetically engineered to express a soluble form of B7.2 Ig Fc under the control of 
a liver-specific promoter which results in colitis with large inflammatory cell infiltration 
[296]. 
In addition to staying with an inflammatory bowel disease centered focus, the 
findings of this Aim can also extend to other applications. Graft vs host disease (GvHD) is 
another chronic inflammatory disease in which MSCs have been utilized in clinical trials 
to treat patients. Similar to treating Crohn’s disease, MSCs that are pre-licensed with IFN-
γ show an enhanced ability to ameliorate the effects of graft vs host disease in preclinical 
models compared to hMSCs that are untreated prior to in vivo delivery [216]. Preliminary 
experiments are currently being conducted within our lab to assess whether MSCs 
delivered within a PEG scaffold can treat murine GvHD compared to MSCs that are 
delivered intravenously. If the results from that study show that administration of MSCs to 
a confined area in vivo can also treat GvHD compared to systemic treatment, it could allow 
for further investigation into whether IFN-γ bound hydrogels could be used for that 
application.  
The results shown in this thesis can also point to venturing outside utilization of IFN-





allows for increasing the immunomodulatory of encapsulated cells. A recent study showed 
that MSCs that were pre-treated with IL-1β significantly ameliorated the development of 
colitis in a dextran sulfate sodium model compared to untreated MSCs [218]. In a similar 
fashion as IFN-γ, hydrogels can be engineered to have bound forms of IL-1β to augment 
MSC activity. Following this logic, more complex systems can be developed where 
multiple cytokines are incorporated into biomaterial scaffold for the purpose of enhanced 
encapsulated cell efficacy. This can also be combined with other technology that is aimed 
to induce recruitment of endogenous cells. In this model, a specific cytokine can be 
included and made to release from the scaffold to allow for recruitment of endogenous cells 
while other tethered and bound forms of cytokines are present to train and activate the cells 






APPENDIX A:  HMSC-ENCAPSULATED INTEGRIN-SPECIFIC 
HYDROGELS FOR VASCULARIZATION AND BONE 








Following the results acquired from Chapter 3, namely that integrin-specificity and 
VEGF-incorporation had a significant effect on vascularization, we wanted to probe 
whether these two parameters could affect vascularization and viability of delivered 
hMSCs in the murine bone defect model. Our hypothesis was that differential 
vascularization induced by these two parameters would result in differential hMSC 
viability and thus induce changes in bone regeneration. To test this, we transduced hMSCs 
to constitutively express a red firefly luciferase construct to enable in vivo tracking within 
the critical-size bone defect. We then encapsulated hMSCs within integrin-specific 
hydrogels that were either functionalized with RGD or GFOGER as well as with different 
doses of VEGF. We conducted longitudinal bioluminescence tracking of hMSCs as well 
as vascularization and bone regeneration analysis through µCT. Our results showed that 
neither integrin-specificity nor VEGF had an effect on hMSC viability, vascularization of 
the defect or bone regeneration.   
A.2 Luciferase-expressing MSCs for in vivo tracking 
HMSCs were transduced to constitutively express a tdtomato / red firefly luciferase 
construct for purposes of in vivo tracking within the critical-size defect model. 





(data not shown). The linearity of bioluminescent signal against cell number was tested by 
seeding the transduced hMSCs into 24 well plates at differing concentrations (Fig. 24). 
Saturating concentrations of luciferin were added to the media and bioluminescent signal 
was acquired by IVIS Spectrum CT. Bioluminescent signal was then plotted against cell 
number and linear regression analysis performed. Linear regression analysis shows an R-







Figure A1: Bioluminescent signal against cell number. A) Different numbers of hMSCs 
expressing constitutive red firefly luciferase were seeded in a 24 well plate and saturated 
concentrations of luciferin added to each well. B) Quantification of bioluminescent signal 






A.3 Longitudinal hMSC number within a critical-size defect are independent of 
hydrogel-based integrin-specificity and VEGF incorporation  
Given that both integrin-specificity and VEGF had significant effects on 
vascularization and bone regeneration in acellular hydrogels, we were interested in 
understanding how integrin-specific hydrogels incorporating VEGF could enhance hMSC 
therapy. The first experiment we wanted to perform was that of hMSC survival with 
altering these two factors, integrin-specificity and VEGF incorporation. Following 
confirmation that bioluminescent signal correlates linearly with hMSC number, we 
encapsulated hMSCs within either GFOGER-functionalized or RGD-functionalized 
hydrogels with or without 50 ng VEGF. These hydrogels were then implanted within 
murine critical-size defects and bioluminescence tracking performed for 6 weeks post-
implantation (Fig. 25). Quantification of bioluminescent flux showed no significant 
differences between GFOGER- or RGD-functionalized hydrogels at all time points tested. 
There was also no significant differences seen between hydrogels functionalized with or 
without VEGF. Notably, all groups showed a consistent trend where bioluminescent signal 
increased until 7 days post-implantation followed by a drop at 14 days to approximately 
10% of implanted bioluminescence intensity. This low level of bioluminescence persisted 






Figure A2: Longitudinal in vivo bioluminescent tracking of hMSCs. Bioluminescent signal 
quantified as photon flux normalized to day 0. N=8-9. Error bars ± SEM. One-way 
ANOVA 
A.3 Vascularization of hMSC-encapsulated integrin-specific hydrogels functionalized 
with VEGF 
While no differences were noted in cell number over 6 weeks post-implantation, 
hMSCs are known to impart effects at short time points as seen through our 
immunomodulation studies. Because of this, we wanted to see whether integrin-specificity 
or VEGF incorporation had an effect on vascularization in hMSC-encapsulated hydrogels. 
HMSCs were encapsulated in either GFOGER- or RGD- functionalized hydrogels and in 
hydrogels functionalized with or without 50 ng VEGF. The hydrogels were implanted 
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within critical-size bone defects and after 8 weeks post-implantation, mice were euthanized 
and blood vessels perfused with Microfil for µCT based imaging of blood vessels 
surrounding the defect area (Fig. 26). Four parameters for vascularization quantification 
were defined: vascular volume, vascular number, vascular thickness and vascular spacing. 
No differences were found in these four parameters between either GFOGER- or RGD-







Figure A3: Vascularization of hMSC-encapsulated hydrogels is independent of integrin-
specificity or VEGF incorporation. A) Representative images of vascularization of defects 





vascular volume, (C) vascular number, (D) vascular thickness and (E) vascular spacing. 
N=6. Error bars ± SEM. One-way ANOVA 
A.4 Bone regeneration of hMSC-encapsulated hydrogels is independent of integrin-
specificity and VEGF functionalization 
While no differences were noted for vascularization between hMSC-encapsulated 
GFOGER- and RGD-functionalized hydrogels or between VEGF incorporating or VEGF-
free hydrogels, we wanted to see if any differences were present in bone regeneration. We 
conducted two different experiments to assess bone regeneration. The first experiment 
consisted of hMSCs encapsulated in either GFOGER- or RGD-presenting hydrogels 
functionalized with either 0 or 50 ng VEGF. For the second experiment, we wanted to 
increase our dose of VEGF to test whether a higher dose of VEGF would elicit a more 
pronounced response. We thus encapsulated hMSCs within either GFOGER- or RGD-
presenting hydrogels functionalized with either 0, 50 or 250 ng VEGF. These hydrogels 
were then implanted within critical-size defects. At 4 and 8 weeks post-implantation, bone 
regeneration within the defect was assessed via µCT imaging. (Fig. 27). For both 
experiments, no significant differences were noted between GFOGER- or RGD-






Figure A4: Bone regeneration in hMSC-encapsulated hydrogels is independent of integrin-
specificity or VEGF incorporation. Quantification of bone regeneration within a murine 
critical-size defect for two independent experiments. Panels (A) and (B) represent bone 
volume quantification at 4 and 8 weeks respectively for one experiment and panels (C) and 
(D) represent bone volume quantification at 4 and 8 weeks respectively for a second 






APPENDIX B: EFFECTS OF ADHESIVE PEPTIDE FOR 







In addition to understanding how integrin-specificity affected vascularization and 
bone regeneration within a murine bone defect, we also wanted to understand if the 
incorporation of ligands affect hMSC immunomodulatory properties. Previous literature, 
as discussed in Chapter 4, noted that hMSCs exhibit a potent anti-proliferative effect on 
activated T-cells, that this effect is cell dose-dependent and that the effect is modulated by 
soluble molecules. We thus chose to probe the notion that ligand can differentially 
modulate hMSC immunomodulation by investigating whether hMSCs encapsulated within 
either adhesive RGD or non-adhesive RDG functionalized hydrogels exhibited differential 
effects on activated T-cell proliferation. Our results showed that hMSCs encapsulated in 
either RGD or RDG hydrogels halted activated T-cell proliferation in a similar fashion 
indicating no effect of adhesive ligand. Furthermore, upon probing the hMSCs for 
immunomodulatory markers, similar levels of IDO and PD-L1 were found between hMSCs 
encapsulated in RGD or RDG hydrogels. Together, this data supports the notion that the 
presence of adhesive ligand has no effect on the immunomodulatory properties of hMSCs.  
B.2 Hydrogel encapsulated hMSCs inhibit T-cell proliferation in a dose-dependent 
manner independently of the presence of an adhesive peptide on hydrogels  
In addition to understanding how integrin-specificity affects bone regeneration, we 
were also interested in understanding how the adhesive property of a material affects the 





hMSCs to inhibit activated T-cell proliferation. For the first experiment, we encapsulated 
different numbers of hMSCs within hydrogels functionalized with either the adhesive RGD 
ligand or the non-adhesive RDG ligand. The hMSC-encapsulated hydrogels were kept in 
culture for 3 days after which, they were placed in co-culture with purified and activated 
human CD4+ T-cells. The hMSCs were allowed to interact with the T-cells for 4 days after 
which the T-cells were collected and assessed for proliferation via EdU incorporation (Fig. 
28). The ratio of hMSCs : T-cells had a significant effect on the proliferation of T-cells 
with higher numbers of hMSCs significantly decreasing T-cell proliferation (Fig. 28B). No 
differences however were seen in between hMSCs encapsulated in either adhesive or non-
adhesive ligands at the same ratio of hMSC : T-cells even though, at the time of co-culture, 
the morphology of the cells in either adhesive or non-adhesive hydrogels were strikingly 
different (Fig. 28A). This finding shows that while hMSCs have a significant effect on T-





    
Figure B1: hMSC-based inhibition of T-cell proliferation is dose-dependent but 
independent of adhesive ligand. (A) Representative images of hMSCs within either RGD- 
or RDG-functionalized hydrogels at the time of initiation of T-cell co-culture. (B) 
Quantification of T-cell EdU indicating T-cell proliferation. N=3-4 separate wells with 
>100 T-cells analyzed per well. Error bars ± SEM. One-way ANOVA * p<0.05, ** 





B.3 HMSC-based inhibition on T-cell proliferation is dependent on the presence of 
IFN-γ in the co-culture but remains independent of adhesive ligand. 
We wanted to further investigate the cause of hMSC-based inhibition of T-cell 
proliferation. Previous literature and results shown previously indicates that hMSCs need 
to be licensed by IFN-γ in order to exhibit immunomodulatory capabilities. Furthermore, 
we hypothesized that we did not previously see an effect of adhesive ligand on T-cell 
proliferation due to IFN-γ exhibiting a saturating effect. We thus conducted an experiment 
where fixed number of hMSCs were encapsulated within either RGD- or RGD-
functionalized hydrogels, cultured for 3 days and then placed in co-culture with purified 
and activated CD4+ T-cells. Additionally, IFN-γ neutralizing antibody was added to the 
cultures to a final concentration of 100, 10 or 1 µg/mL (The ND50 for the antibody is ~30 
µg/mL). After 4 days, T-cells were collected and proliferation assessed via EdU 
incorporation (Fig. 29). IFN-γ neutralizing antibody at a concentration of 100 µg/mL 
resulted in a significant increase in T-cell proliferation in conditions in which hMSCs were 
encapsulated in either RGD- or RDG-functionalized hydrogels compared to conditions of 
IFN-γ neutralizing antibody at concentrations of 10, and 1 µg/mL. Importantly, for each 
dose of IFN-γ neutralizing antibody, there were no differences in T-cell proliferation for 






Figure B2: hMSC-based inhibition of T-cell proliferation is significantly affected by IFN-
γ but independent of adhesive ligand. HMSCs encapsulated in either RGD- or RDG- 
hydrogels were incubated with activated T-cells for 4 days in the presence of differing 
concentrations of IFN-γ neutralizing antibody. (A) Quantification of T-cell proliferation as 
assessed by EdU. N=3-5 separate wells with >100 T-cells analyzed per well. Error bars ± 











































































































B.4 IDO and PD-L1 expression in hMSCs encapsulated in adhesive or non-adhesive 
hydrogels is dependent on the presence of T-cells but independent of the adhesive 
property of the hydrogel 
Noting that hMSCs in either RGD- or RDG-functionalized hydrogels with differing 
concentrations of IFN-γ neutralizing antibody still showed no effect of adhesive or non-
adhesive ligand on T-cell proliferation, we wanted to remove the step of measuring T-cell 
activity to focus on whether any effect of adhesive ligand can be there. The rationale of 
this being that if a difference is imparted on the encapsulated hMSCs, it is possible that 
because we are measuring T-cell activity, the measurement is too far from the effect that it 
is not accurately measured. Thus, to directly measure the activity of the hMSCs, we chose 
to stain for expression markers IDO and PD-L1 as these two proteins have been implicated 
in the immunomodulatory ability of hMSCs both in previous literature. In addition to the 
testing whether the adhesive property of the hydrogel affected hMSC IDO and PD-L1 
expression, we also wanted to test whether PEG weight percent had an effect. hMSCs were 
thus encapsulated in either RGD or RDG-functionalized and in either 6% or 12% PEG 
weight percent hydrogels and then either co-cultured with purified and activated CD4+ T-
cells or cultured without T-cells. After 4 days, hydrogels were degraded, hMSCs extracted 
and stained for IDO and PD-L1 followed by assessment by flow cytometric analysis (Fig. 
30). IDO and PD-L1 were significantly upregulated in hMSCs encapsulated within 
hydrogels at equal PEG weight percent and co-cultured with T-cells compared to those not 





hMSCs encapsulated in 6% PEG weight percent hydrogels in co-culture with T-cells 
compared to hMSCs encapsulated in 12% PEG weight percent hydrogels in co-culture with 
T-cells. Importantly, among equal PEG weight percent and T-cell condition, there were no 
significant differences between hMSCs in adhesive hydrogels or non-adhesive hydrogels. 
This further supports the conclusion that hMSC-based immunomodulation is not based on 
the presence of adhesive ligand.  
 
Figure B3: IDO and PD-L1 expression on hMSCs is dependent on T-cell co-culture and 
PEG weight percent but not hydrogel adhesive property. HMSCs were encapsulated in 
either 6% or 12% PEG weight percent hydrogels with either RGD- or RDG-functionalized 
onto the hydrogel. Hydrogels were then either incubated with activated T-cells or with no 
T-cells. After 4 days, hydrogels were degraded and hMSCs stained for IDO and PD-L1 





(A) IDO and (B) PD-L1. N=3-4 separate hydrogels with 5000 hMSCs analyzed per 













C.1 HMSCs encapsulated within tethered IFN-γ hydrogels exhibit significantly more 
healing than IFN-γ hydrogels without hMSCs in a colonic wound model 
An initial pilot study was performed to ascertain the feasibility of the implanting 
hMSC-laden hydrogels in mouse colonic wounds. This study also determined whether cys-
IFN-γ hydrogels without hMSCs would have an effect compared to cys-IFN-γ hydrogels 
with encapsulated hMSCs.  This animal experiment was performed with the approval of 
the University of Michigan Animal Care and Use Committee within the guidelines of the 
Guide for the Care and Use of Laboratory Animals and in accordance with the US 
Department of Agriculture (USDA) Animal and Plant Health Inspection Service (APHIS) 
regulations and the National Institutes of Health (NIH) Office of Laboratory Animal 
Welfare (OLAW) regulations governing the use of vertebrate animals. Colonic wounds 
were induced in a method similar to previously published protocols [289]. Briefly, male (8 
weeks old) C57-Black6 mice (Jackson Laboratory) were anaesthetized by intraperitoneal 
injection of a ketamine (100 mg/kg)/xylazine (10mg/kg) solution. A high-resolution 
miniaturized colonoscope system equipped with biopsy forceps (Coloview Veterinary 
Endoscope, Karl Stortz) was used to biopsy-injure the colonic mucosa at 5 sites along the 
dorsal artery. Wound size averaged approximately 1 mm2. 50 µL hydrogel injections were 
performed 1 day following wounding with the aid of a custom-made device comprising a 
29-gauge needle connected to a small tube. Endoscopic procedures were viewed with high-





was digitally photographed at day 1 and day 5 and resulting wound images for which the 
wound area was calculated by a blinded observer using ImageJ. 
Results from day 5 quantification of colonic wound closure show a significant 
increase in the wound closure for mice treated with cys-IFN-γ hydrogels with encapsulated 
hMSCs compared to those treated with cys-IFN-γ hydrogels without hMSCs and control 
animals that were injected with saline (Fig. C1). 
 
Figure C1: Representative images and quantification of colonic wound closure at 5 days 





with N=3 wounds per mouse and each point indicating the average of one mouse. N=3-4 












A minimally invasive, translational method to deliver hydrogels to the heart through the 
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Light-triggered in vivo activation of adhesive peptides regulates cell adhesion, 






























































































Synthetic matrices reveal contributions of ECM biophysical and biochemical properties to 


































































































































































































Parallel droplet microfluidics for high throughput cell encapsulation and synthetic microgel 
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